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Histones are group of positively charged proteins that form nuclear cores for building 
chromatins with double stranded DNAs. During cell death, the nuclear breakdown products 
can be released extracellularly and rapidly cleared by leucocytes and macrophages. However, 
during extensive and rapid cell death, such as in severe trauma, sepsis, and necrotising 
pancreatitis, the nuclear breakdown products cannot be immediately cleared and can be 
degraded to release histones. Over recent years, the toxicity of extracellular histones has been 
discovered, including cytotoxicity through interrupting cell membranes, stimulation of 
cytokine release and inflammatory responses and activation of coagulation cascades. High 
levels of circulating histones can cause injury to many distant organs, such as the lungs, heart, 
liver and kidneys, and may contribute to multiple organ failure in critical illness. Therefore, it 
is important to detoxify histones in order to reduce distant organ damage and rescue these 
critically ill patients. 
It is known that activated protein C is able to cleave histones to reduce their toxicity. 
However, due to its sideeffects, it has been withdrawn from clinical use. Heparin, a 
commonly used anticoagulant, is able to bind to histones and reduce their toxicity. However, 
heparin may also cause side effects, such as heparin-induced thrombocytopenia, preventing 
its clinical application because histones also cause severe thrombocytopenia. Anti-histone 
antibodies have been reported to reduce histone toxicity and rescue mice with sepsis. 
However, no clinically usable anti-histone antibodies are available. In this study, I focused on 
the development of anti-histone antibody fragments.  
In this project, a murine anti-histone single chain variable fragment (scFv) was designed and 
produced. After confirming its roles in detoxifying histones, the anti-histone scFv was 
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humanised using the human IgG framework and mouse anti-histone complementarity-
determining regions (CDRs) to generate a humanised anti-histone scFv (HahscFv). The 
specificity of the HahscFv was confirmed by Western blotting, and its role in detoxification 
of histones was also verified in vitro. In addition, I have developed a new approach to 
produce human anti-histone antibody fragments. This approach includes isolation of anti-
histone antibodies from sera of patients with systemic lupus erythematosus (SLE) using 
affinity purification, determination of amino acid sequences of the isolated heavy and light 
chains, using tandem mass spectrometry (MS/MS) and reproduced these antibody fragments 
(scFv) using recombinant DNA technology.  The specificity and binding affinity of this 
purified human anti-histone antibody were determined. The functional roles of the scFv with 
highest affinity to histones were verified both in vitro and in vivo.  
Moreover, I have also screened for the presence of histone-binding proteins in human serum 
using a pull down assay with high stringency. I found that both prothrombin and anti-
thrombin are strongly associated with histones. Furthermore, I have demonstrated the 
mechanism of histone-induced thrombin generation. This work improves the understanding 
of why histones are potent pro-coagulants.  Importantly, the anti-histone scFv is able to block 
this process, suggesting a potential that anti-histone therapy, and in particular anti-histone 
antibodies, may reduce coagulation activation and the development of disseminated 
intracellular coagulation (DIC) in critical illness. Future work will be along these lines to 
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Chapter 1 General Introduction 
 
1.1 Critical illness  
In general, critically ill patients encompass those admitted to the intensive care unit (ICU) 
due to the requirement for intensive management and careful monitoring. The conditions for 
such a requirement include sepsis, trauma, surgery, pancreatitis, ischemia-reperfusion injury 
and many other conditions that result in systemic complications. These culminate in an 
increasing number of failing organs that typically begin with respiratory and cardiac failure, 
leading on to multiple organ failure (MOF). Such sequence of events invariably has 
catastrophic implications to patient outcome [1]. The number of patients treated in ICU is 
increasing with Intensive Care National Audit and Research Centre (ICNARC) data shown in 






Figure 1.1 Number of Admissions in critical care units by year in the UK. This figure is 
adapted from reference [2].  
 
1.1.1 Critical illness and inflammatory response 
The inflammatory response is a complex biological process that aims to protect the host from 
harmful stimuli such as infection or damaged cells. The purpose of this response is to 
eliminate the source of cell injury, remove cellular debris, and to initiate tissue repair. As a 
generic host response to insult or injury, it is considered part of the innate immune response.  
Molecular components of the inflammatory response are divided into cytokines (e.g. 
Interleukin (IL)-1β, IL-6, IL-8 and Tumour necrosis factor alpha (TNFα)), plasma proteins, 
acute phase proteins (APP) and cellular components such as leukocytes and the endothelium.   
As critical illness is usually triggered by a noxious stimulus, e.g. infection or non-microbial 
causes such as trauma or infarction, the systemic inflammatory response syndrome (SIRS) 
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almost always ensues [6]. Table 1.1 below illustrates the criteria used to assess the 
development of SIRS [7] with the presence of two or more of these criteria required to 
establish a diagnosis of SIRS.  Invasive infection on the background of SIRS is defined as 
sepsis, which is a multi-factorial syndrome arising from the host response to infection and is 
associated with extensive systemic cell and tissue damage [8]. The American College of 
Chest Physicians and the Society of Critical Care Medicine [6, 9], defined as the development 
of organ failure in the course of sepsis as “severe sepsis”, while the presence of persistent 
acute circulatory failure despite adequate volume resuscitation as “septic shock”.  
 
Table 1.1 Criteria for the diagnosis of SIRS. 
Criterion Value 
Temperature (°C) >38 or <36 
Heart rate (beats per minute)  > 90  
Respiratory rate  >20 or PaCO2 <32 mmHg 
White blood cell count >12,000 or >10% neutrophils 
 
 
Although the diagnosis of the systemic inflammatory response in critically ill patients 
currently relies mostly on clinical criteria, many researchers have identified promising 
biochemical and/or immunological parameters that are elevated in SIRS, such as interleukins 
[10], adrenomedullin [11], extracellular phospholipase A2 [12], C-reactive protein (CRP) [13] 
and most recently nuclear break down products such as extracellular histones and 
nucleosomes [14]. Therefore, some authors have suggested that it might be possible, if 
supported by adequate clinical and epidemiologic studies, to better characterise and diagnose 
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systemic inflammation in critical illness through use of these biomarkers [6]. In general, 
intensivists feel that the current diagnosis of SIRS is not sufficiently specific and needs 
strengthening with inclusion of biological parameters. 
 
1.1.2 Critical illness and coagulation 
The activation of coagulation is a process by which fibrin clots are formed to stem blood loss. 
This is highly regulated to prevent excessive bleeding (haemorrhage) but not cause 
thrombosis. This process is also important in wound healing/repair and also prevents 
dissemination of microorganisms into the circulation. However, when coagulation activation 
is excessive due to continued presence of triggering factors and/or unchecked through 
depletion of regulatory factors, it can be detrimental to the host. Such an uncontrolled 
response could lead to haemorrhage through consumptive coagulopathy (through a significant 
decrease in the level of coagulation factors and platelet counts) and also microvascular 
thrombosis which can cause multiple organ failure (MOF). The condition is then referred to 
as disseminated intravascular coagulation (DIC), which the International Society on 
Thrombosis and Haemostasis (ISTH) has defined as “significant reduction in platelet counts 
and fibrinogen levels, significant prolongation in prothrombin time (PT) and substantial 
increment in fibrin-related markers” [15]. In essence, DIC reflects the increased generation of 





1.1.2.1 Thrombin generation  
Thrombin plays a pivotal role in the control of coagulation and fibrinolytic processes. It can 
be immediately pro-coagulant in converting fibrinogen to fibrin, anticoagulant in terms of 
thrombomodulin-dependent protein C activation and pro-fibrinolytic through stimulating 
endothelial cells to release tissue plasminogen activator [17-19]. Disturbance or imbalance in 
these pathways can alter the clinical phenotype of increased bleeding and/or increased 
thrombosis in the microcirculation. Under physiological conditions, tissue factor exposure 
triggers coagulation activation that leads on to thrombin generation, which then back-
activates the intrinsic pathway coagulation factors to amplify thrombin generation. 
Dysregulation of this process leads to propagation of thrombin generation and adverse 
consequences, if unchecked. More recently, histone H4 has been reported to promote 
prothrombin auto-activation into thrombin [20]. If Arg-320 is mutated, it could block 
prothrombin autoactivation [21]. H4 bound to prothrombin had been demonstrated by 
fluorescence titrations, and thus promoted prothrombin cleavage into various products e.g. 
prethrombin-1, prethrombin-2 and fragment 1.2. Moreover, H4 bound to prothrombin to 
induce a collapsed conformation, and further caused various conformations of inter-kringle 
linker domain that determined prothrombin’s functions [20]. If this process is physiological, 
which is currently unproven, this would be a means by which thrombin can be generated 
without activation of the coagulation cascade.  
 
1.1.2.2 Prothrombinase  
A key step in thrombin generation is in the enzymatic assembly that enables conversion of 
the zymogen prothrombin into the enzyme thrombin. This complex formed by factor (F) Xa, 
co-factor FVa, prothrombin in the presence of calcium ions and phospholipid is referred to as 
the prothrombinase complex [22]. Prothrombin, also known as coagulation factor II normally 
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circulates in the blood at a concentration of approximately 0.1 mg/mL [23]. It is a single 
chain protein composed of fragment 1 (F1) (residues 1 – 155), F2 (residues 156 – 271) and 
the protease domain (α-thrombin) (residues 272 – 579). In F1, there is a Gla and a kringle-1 
domain with F2 containing kringle-2 and the A and B chains of thrombin in α-thrombin. 
Prothrombin is linked by three flexible linkers which individually ligate between Gla domain, 
kringle-1, kringle-2 and A chain [24] (Fig. 1.2). In the prothrombinase complex, there are two 
cleavage pathways [25]. Prothrombin is initially cleaved at Arg-271 to split into two parts: 
the F1 and F2 complex, and prothrombin-2. Prothrombin can also be cleaved at Arg-320 to 
form meizothrombin (Fig. 1.2) because A and B chains are connected by a disulphide bond 
(Cys-293 and Cys-439) [25].  
 
 
Figure 1.2 Schematic diagram for prothrombin structure. This figure is adapted from 




1.1.3 Critical illness and cell death 
Extensive and uncontrolled cell death plays a key role in the development of MOF during 
critical illness [26, 27]. After extensive cell death, cellular contents including the intra-
nuclear nucleosomes (DNA-histones complexes) are released into the circulation and has 
been reported in various diseases such as cancers, sepsis and trauma [28]. During tissue 
damage and cell death, chromatin is cleaved into oligo- and mono-nucleosomes, which are 
then released extracellularly [29] and further degraded into individual histones (H1, H2A, 
H2B, H3 and H4), heterodimers (H2A/H2B and H3/H4) [30] as well as free DNA [31].  
However, these are rarely detected in blood unless there is extensive cell death [28] as they 
are rapidly cleared by the liver [32].  
 
1.2 Extracellular histones and toxicity 
Histones are basic proteins usually found within the nucleus of eukaryotic cells.  There are 5 
members of the histone (H) family: H2A, H2B, H3, H4 (core histones) and H1 (linker 
histone) [33]. The core histones share common structural characteristics, consisting of a 
central helix flanked by two helix-strand-helix motifs. Nucleosomes are formed by an 
octomeric protein core consisting of heterodimers H2A/H2B and H3/H4 with 146-base pairs 
(bp) of DNA wrapped around them [34]. The linker histone (H1) binds to non-nucleosomal 
DNA and links individual nucleosomes together, allowing for higher order chromatin 
structures to be formed [35]. Whilst histones are essential building blocks within cells in 
forming the basis of chromatin, their effects outside the cell can be extremely toxic [14]. 
Work from our group has shown that extracellular histones bind phospholipids on membranes 
to cause profound calcium influx [36, 37] and subsequent cell damage. This indiscriminate 
toxic effect of histones is critical to increasing coagulation activation [38], platelet 
aggregation [39], pro-inflammatory cytokine release [40, 41] and endothelial damage [14]. 
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The release of extracellular DNA and histones from neutrophils during neutrophil 
extracellular trap (NET) formation also facilitates thrombus formation and has shown 
relevance in animal models of deep vein thrombosis, transfusion-related acute lung injury, 
cancer, trauma and sepsis [14, 36, 42-44]. 
 
1.2.1 Extracellular histones in coagulation and thrombosis 
The role of extracellular histones in the promotion of coagulation and thrombosis is 
becoming increasingly characterised as outlined in Figure 1.3. The general pro-coagulant 
properties of histones include endothelial damage with released von Willebrand factor (vWF) 
mediating leucocyte/platelet recruitment and loss of thrombomodulin (TM)-dependent 
protein C anticoagulant effects [14, 45, 46]. In vivo, histone infusion in mice results in rapid 
thrombocytopenia (significant reduction in platelet count) with histone and platelet staining 
in the lungs [39, 47]. Further evidence to support the role of histones in the activation of 
coagulation was demonstrated by our group. In mouse models, plasma thrombin–anti-
thrombin (TAT) complexes, i.e. a marker of thrombin generation and therefore, of 
coagulation activation, were significantly elevated following either trauma (endogenous 
histone model) or histone infusion (exogenous histone model) [48]. Pathologically, the lungs 
were the predominantly affected organ with neutrophil infiltration, pulmonary oedema, 
haemorrhage, and microvascular thrombosis [48]. The formation of thrombi in lungs strongly 
supports the hypothesis that histone-triggered coagulation activation is involved in lung 





Figure 1.3 Role of histones in coagulation. This figure is adapted from references [20, 38, 
49, 50]. 
 
Histones induce platelet aggregation in vitro with H4 invoking the strongest response [39].  
Mechanistically, histones bind to platelets, induce calcium influx, and recruit coagulation 
factors such as fibrinogen [39]. Fibrinogen then cross-links platelet integrin αIIbβ3 which in 
turn results in large platelet aggregates [39]. Furthermore, Semeraro F et al demonstrate that 
histones dose dependently enhance thrombin generation in platelet rich plasma (PRP) in a 
Toll-like receptor (TLR) 2 and 4-dependent mechanism. Activation of these receptors induces 
intra-platelet signalling through extracellular stimuli-responsive (ERK), Akt, p38, and NFB 
Intrinsic pathway Extrinsic pathway
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Figure 1.4.1 Histones in coagulation
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[51]. More recently, polyphosphates have been found in human platelet dense granules to act 
as activator of factor XII and regulate coagulation and fibrinolysis. The purified 
polyphosphate with histones and FXII have been demonstrated to induce thrombin generation 
[52]. Moreover, blocking TLR2 and TLR4 using specific antibodies reduced platelets 
activation and thrombin generation in the presence of histones. Therefore, histones could 
induce a procoagulant phenotype via TLR2 and TLR4 [52]. 
 
1.2.2 Extracellular histones in innate immunity 
As a feature of the innate immune response, neutrophils can eliminate microbes through 
either phagocytosis, generation of reactive oxygen species (ROS) and through degranulation 
of anti-microbial molecules. Neutrophils are the most abundant form of leucocytes and act as 
the first line of defence against invading pathogens [53]. Along with basophils and 
eosinophils, they form the polymorphonuclear (PMN) cell family. They are derived from 
stem cells in the bone marrow and have a short half-life when in circulation [54]. As a 
hallmark of acute inflammation, neutrophils are recruited and infiltrate a site of infection 
through chemotaxis [55].   
Recently, it has been demonstrated that activated neutrophils can immobilise and kill 
invading microorganisms through the release of extracellular traps (NETs).  During NETosis, 
a distinct form of active cell death, neutrophils unravel chromatin and extrude DNA and 
histones along with myeloperoxidase (MPO), cathepsin G and neutrophil elastase (NE) into 
the extracellular space. Studies have demonstrated that lysine-rich histones (H1, H2A, and 
H2B) and histone fragments, from shrimp [26], fish [20, 27–30], frog [31], chicken [32, 33], 
and mammals [34–38] share antimicrobial activity.  
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Pathways to NETosis include histone deimination by peptidyl-arginine deiminase 4 (PAD4) 
[56] and the involvement of NE and NADPH oxidase [57, 58]. PAD4 converts certain 
arginine residues on the core histones to citrulline [59]. Eliminating the positive charge at this 
residue, theoretically results in unravelling of the compact structure of the chromatin and 
causing chromosomal decondensation, followed by plasma membrane rupture. 
A large variety of bacteria stimulate NETs including (Table 1.2), Staphylococcus aureus [60], 
Streptococcus dysgalactiae [61], Klebsiella pneumonia [58], Listeria monocytogenes [62], 
Mycobacterium tuberculosis [63], Haemophilus influenza [64], and Shigella flexneri [65]. 
Surface components of both Gram-positive and negative bacteria such as lipoteichoic acid 
and Lipopolysaccharides (LPS) have also been shown to trigger NETosis [66]. This 
observation has characterised NETs as part of the innate immune response [66]. The release 
of extracellular DNA and histones from NETs facilitates thrombus formation through platelet 
recruitment thereby limiting the dissemination of the invading microorganism into the 
systemic circulation [67]. 
Certain pathogens such as Staphylococci and Streptococci have evolved to evade this 
mechanism through the release of virulence factors that degrade NETs [68]. Another 
evolutionary mechanism developed by pathogens to suppress NETs can be observed in Cystic 
Fibrosis (CF). Clinical isolates from the lung of CF patients show a mucoid phenotype that 
makes Pseudomonas aeruginosa less sensitive to NET inhibition of growth [69]. Bacterial 
growth thrives despite the accumulation of NETs in these infected organs, with NETs 





Table 1.2 Inducers of NETs formation. 
NETosis inducer Reference 
HOST FACTORS 
Extracellular histones Ambras et al., 2013 [48] 
GM-CSF + C5a       Yousefi et al., 2009 [70] 
IL-8 (CXCL8)      Gupta et al., 2005 [71] 
MIP-2(CXCL2)      Marcos et al., 2010 [72]  
Singlet oxygen      Nishinaka et al., 2011 [73] 
Platelet activating factor (PAF)     Yost et al., 2009 [74] 
Syncytiotrophoblast microparticles 
(STBM)   
Gupta et al., 2005 [75] 
OTHERS 
Glucose oxidase      Yost et al.,2009 [74] 
Calcium ionophore (ionomycin)     Parker et al., 2012 [76] 
Phorbol myristate acetate (PMA)   Brinkmann et al.,2004 [65]; Remijsen et al., 
2011 [77] 
LPS (Bacterial component) Brinkmann et al.,2004 [65] 
 
In spite of the beneficial role that NETs play in innate immunity, pathological properties have 
been ascribed due to their ineffective degradation and clearance. One such effect is the 
development of autoimmunity, which has been shown in patients with atherosclerosis [78], 
Felty's syndrome [79], rheumatoid arthritis (RA) [80], small-vessel vasculitis (SVV) [81], 
and systemic lupus erythematosus (SLE) [82]. 
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SLE is an autoimmune disorder characterised by the development of autoantibodies to 
neutrophil proteins, DNA and histones in particular [83], which are highly immunogenic 
[84].  These antigens and antibodies (Ab) form immune complexes that are either formed in 
situ or can be deposited in the kidneys contributing to organ failure in this disease [85]. 
Infections can result in a flare up of the disease due to the induction of the innate immune 
response and the production of NETs and therefore self-antigens. The presence of histones on 
NETs may be responsible for the ineffective clearance of NETs by degrading enzymes such 
as DNase1 and therefore resulting in a vicious circle of disease progression [82]. 
 
1.2.3 Extracellular histones and neutrophil recruitment, and activation 
Neutrophil congestion inside lung capillaries in mice infused with histones was first reported 
by Xu and colleagues [14] and further characterized by our group [48].  Pulmonary alveolar 
capillaries become obstructed with neutrophils following significant neutrophil infiltration in 
the lungs of histone-infusion, septic, and trauma mouse models. In mice infused with 
histones, Myeloperoxidase (MPO) staining is found inside alveoli, indicating MPO release 
from neutrophils following histone infusion [48]. Similarly, in vitro histone-stimulated 
neutrophils, released significant MPO. MPO enhances the production of hypochlorous acid, 
which acts as an antimicrobial agent but can also damage host cells [86].  
Furthermore, our group has demonstrated that histones directly induce NETs formation both 
in vitro and in vivo.  Histone-treated neutrophils induced NETs within 3 hours to comparable 
levels to those induced by PMA stimulation (known inducer of NETs).  Examination of the 
lungs of histone-infused mice demonstrated Citrullinated histone H3 (CitH3) positivity (a 
marker of NETs) [48]. Specifically, co-infusion with murine anti-histone single chain 
variable fragment (MahscFv) significantly abrogated this effect [48]. Taken together, histone-
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induced NETs formation may serve as a mechanism for neutrophil congestion and thrombosis 
in lungs, which would exacerbate tissue injury [87], increase coagulation activation and pro-
inflammatory cytokine release. This process has relevance in animal models of deep vein 
thrombosis, transfusion-related acute lung injury, cancer, trauma and sepsis [6, 9-12]. 
 
1.2.4 Extracellular histones and acute lung injury (ALI) 
Following histone-infusion, mice die rapidly (within 4 hours) after developing cyanosis and 
dyspnoea, an indicator of pulmonary and cardiac failure. Pathological examination shows the 
lungs to be the predominantly affected organ with severe oedema, multifocal alveolar 
haemorrhage and congestion. Pathological changes in other organs (kidney and liver) were 
less obvious, except for occasional thrombus and vacuole formation. Specifically, histone-
induced lung injury can be significantly reduced by co-infusion of MahscFv (10 mg/kg) [48].  
Similar pathological changes are observed in a Gierer mouse model of severe trauma, 
demonstrating that endogenous histones are involved in lung injury, which could also be 
abrogated by infusion of the MahscFv (10 mg/kg) [48]. Moreover, the full development of 
ALI was induced by LPS, IgG immune complexes, or C5a in mice models requiring 
complement receptor C5aR and C5L2. H3 and H4 had been identified in bronchoalveolar 
lavage fluid (BALF) after C5a–induced ALI [88]. Taken together, these data indicate that the 
lungs are the most susceptible organ to the toxicity of circulating histones probably because 






1.2.5 Mechanisms of cytotoxicity of extracellular histones 
Histone increased the permeability of cellular membranes [89]. This is most likely due to the 
positively charged histones binding to negatively charged phospholipids [34], which are the 
main structural components of plasma membranes [90]. Our group demonstrated that the 
membrane-binding property of extracellular histones is the major mechanism of toxicity. In 
vitro, fluorescein isothiocyanate (FITC)–labelled histones bind to endothelial cell membranes 
and in vivo histone-infusion generates histone staining on endothelial cell membrane surfaces. 
Immediately following histone treatment, histones binding to endothelial cells changes the 
membrane potential due to elevations in intracellular Ca
2+
. Furthermore, histone-induced cell 
damage can be inhibited when extracellular Ca
2+
 is removed [48]. TLR4- and TLR2-
neutralizing antibodies did not block the Ca
2+
 influx and showed no protective effect on 
cultured endothelial cells treated with histones. This demonstrates that extracellular histones 
bind phospholipids on cell membranes to cause calcium influx [48] and subsequent cell 
damage, and that activation of TLRs is not the major pathway for histone toxicity, at least to 
endothelial cells.   
 
1.3 Neutralisation of histone toxicity  
Following the discovery of extracellular histones toxicity, neutralising histone-induced 
toxicity has been demonstrated using antibodies to histones or activated protein C (APC) 
[14]. APC was found to cleave extracellular histones thereby reducing their toxicity. Co-
infusing APC and histones resulted in significant improvement in mice survival [14]. Since 
this discovery, a series of substrates have been reported to reduce histone-induced toxicity, 
such as C-reactive protein (CRP) [91], heparin [92] and 10% Fetal calf serum (FCS) [93], 




1.3.1 Detoxification of extracellular histones 
Recently, our group has found that the immune response plays a key role in detoxifying 
circulating histones. High levels of acute phase proteins (APP) are produced in response to 
infection, inflammation, injury and malignancy [14], which are regulated by cytokines such 
as interleukin (IL)-1, IL-6, IL-8 and TNFα [15-17]. We have shown that extracellular 
histones trigger leucocytes to release pre-synthesized IL-6, which in turn induces CRP 
release. CRP can then complex with histones to prevent histone-membrane binding. 
Histological examination showed that CRP-infusion reduced lung oedema, haemorrhage and 
thrombosis in mice challenged by a lethal dose of histones to rescue these mice.  Clinically, 
CRP takes 4-6 hours to reach levels that neutralize the toxicity of circulating histones. This 
has important clinical implications in defining a time-critical window for histone-targeted 
therapy. 
 
1.3.2 Histone toxicity is buffered by plasma  
Pemberton et al [93] demonstrated that exogenous histones are toxic to cultured mouse 
intestinal epithelial cells in serum-free medium, but toxicity was reduced in 10% FCS. 
Furthermore, they showed that the addition of histones to plasma induces protein 
precipitation characterised by increased turbidity [93] and protein depletion following 
centrifugation of histone-treated plasma. Pemberton et al identified a total of 36 histone-
associated plasma proteins by shotgun proteomic analysis. These included complement 
related proteins, coagulation factors, protease inhibitors and lipoprotein-associated proteins 
[93].   
17 
 
To clarify this in a clinical context, our group used serum from trauma, sepsis and acute 
pancreatitis patients and found that it was toxic to cultured endothelial cells once histone 
levels exceeded 50 µg/mL. Using normal serum supplemented with calf thymus histones, a 
similar dose response was seen.  This therefore suggests that both serum and plasma is able to 
buffer up to 50 µg/ml histones when in the circulation but when this dose is exceeded, 
histone-induced toxicity can be observed.  Indeed, investigating a cohort of patients with non-
thoracic blunt trauma and examining the development of respiratory failure showed that this 
cutoff level for circulating histones was clinically relevant. Specifically, 76.5% of patients 
with circulating histones equal to or greater than 50 µg/mL, developed respiratory failure 
compared with 18.8% of patients below this threshold [48]. 
 
1.3.3 Heparin  
The nonspecific binding of heparin to histones by Western blot analysis was reported in 1999 
[94]. This study has further confirmed that heparin binds to histones and ribosomal proteins 
with high affinity after cell necrosis, whereas heparin did not bind to live cells [95]. Recently, 
non-anticoagulant heparin has been shown to prevent histone-induced toxicity both in vitro 
and in vivo at a low-dose [92].   
 
1.3.4 Anti-histone antibodies 
Autoantibodies to histones have been found in autoimmune diseases especially in SLE[96, 
97]. Murine monoclonal antibodies (mAbs) to histones (LG2-1, LG2-2 and BWA3) have 
been developed and produced by Monestier et al. in 1993 in order to investigate chromatin 
proteins in the expansion of auto-reactive B cells [98]. LG2-1 binds H3 at residues 30-45, 
whereas LG-2 targeted H2B at residues 1-13. More interestingly, BWA3 was found to bind 
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both H2A and H4 at residues 1-20 and 1-29, respectively. These three antibodies bind to 
histones; because their complementarily determining regions (CDRs) are negatively charged 
and could interact with the positively charged histones [98]. The BWA3 mAb had been firstly 
used in 2009 to reduce histone-induced toxicity in vivo [14]. Since then, several researchers 
have used the BWA3 mAb to protect against histone-induced toxicity and lethality in various 
diseases models [43, 48, 88, 99, 100]. Anti-histone antibody protected mice against 
transfusion-related acute lung injury, and also attenuated acute lung injury in a murine model 
of trauma and in a histone-infusion mouse model [43, 48, 88]. Moreover, antibodies to 
histones neutralized the immunostimulatory effects of histones, inhibited intra-renal 
inflammation and neutrophil infiltration [99], and reduced neutrophil recruitment by necrotic 
cells [100].  
 
1.4 Antibody structure and function 
Immunoglobulins or antibodies are secreted by B Cells, in order to specifically bind and 
neutralise pathogens (such as bacteria and viruses) beyond innate immune responses [101]. 
There are several classes of antibodies, IgG (146 kDa) comprises 70-75% of circulating 
immunoglobulins, IgM (194 kDa) comprises about 10%, IgA (192 kDa) comprises about 15-
20% and IgD comprises only less than 1% [102], as well as IgE [103]. Moreover, IgM and 
IgD make up the primary response, and IgA, IgG, and IgE are related to secondary response. 
An antibody (e.g. IgG) normally consists of 2 copies of heavy and light chains (Fig 1.2) [104] 
to form a “Y” shape protein held by disulphide bounds [101]. Each heavy (~55 kDa) and 
light (~25 kDa) chain has a constant and variable region, respectively [103]. Each variable 
domain has three hypervariable loops to determine antigen specificity known as 
complementarity determining regions (CDRs) [101]. The CDRs in heavy and light chains can 
be specific to determine the binding sites of antigen, especially heavy chain CDR3 (Fig. 1.4) 
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[105, 106]. The light chain has only one constant domain whereas the heavy chain has three 
domains: CH1 is the first domain link with variable region and following is CH2 and CH3, 
form the Fc fragment of the antibody. The Fc fragments have their own functions, for 
example, C1q also can bind to CH2 domain on IgG [107] and interacts with Fc receptors 
[104]. The heavy chain constant domains can be altered, yet the antigen specificity is still 
remained [104]. 
Neutralization, opsonization and complement activation are the major function of antibodies 
in the adaptive immune system. (a) Neutralization is the best known function. Antibodies 
bind to invading pathogens or their toxic products in order to block their interaction with the 
host cells [101]. (b) Opsonization is a process by which an antibody-antigen (e.g. bacteria, 
viruses, as well as fungi [108]) complex is eliminated by a phagocyte [101]. (c) Once 
antibodies bind to antigens, complement classical pathways are activated by C1q that bind to 
antibody-antigen complexes. Moreover, complement components are either deposited on a 




Figure 1.4 Typical antibody structure (known as IgG). This figure is adapted from 
reference [104]. Light and heavy chains are linked by disulphide bounds. Each chain contains 






1.5 Antibody production  
Antibodies are normally secreted from B lymphocytes of the adaptive immunity, to eliminate 
invading pathogens (e.g. bacteria, viruses and fungi) by specifically binding the antigens. 
Despite their intended protective nature, antibodies can be harmful. Serum containing 
polyclonal antibodies obtained from human placentas could prevent measles in the late 1930s 
[110]. However, it was noticed that mixed immunoglobulins from serum could induce 
systemic harmful reactions when they were intravenously injected into immunodeficient 
patients [111] thus purified IgG polyclonal antibodies were preferred  [112]. A breakthrough 
was made by Kohler and Milstein [113] who first developed monoclonal antibody specficity 
to an eptitope in late 1970s. This opened a new gate for antibody therapy, as well as for 
molecular biology research [113]. With the development of recombinant DNA technology 
[114], antibody fragments could also be produced in E. coli [115] after screening the phages 
with high affinity to specific epitopes using phage display [116], RNA-display [117] and 
even DNA-display [118]. However, most antibody fragments expressed in E.coli are not 
soluble [119], spurring efforts to investigate refolding methods [119, 120] to produce soluble 
antibody fragments that could be used for futher applications [121].  
 
1.5.1 Polyclonal antibodies 
Polyclonal antibodies, as the name suggests, recognize at least one or more epitopes to the 
antigen. In 1890, the immunized rabbit serum with tetanus toxin rescued tetanus-challenged 
animals [122], suggesting that potential molecules in the serum can specificially target the 
tetanus toxin to reduce its toxicity. This was later called ‘serum therapy’ [123]. Injected 
serum however, could cause hypersensitivity reactions [123], therefore purified antibody-
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based therapies [124] are more appropriate. Efficiency may be further enhanced by 
intravenously injecting purified polyclonal antibodies into the host [125].  
Polyclonal antibodies are normally isolated from hyper-immunised rodents or rabbits [126, 
127]. Subsequently, large-scale polyclonal antibodies could also be obtained from 
hyperimmunised cattle using transgenic procedures [128]. However, the binding efficiency of 
polyclonal antibodies to antigen is low, as the functionality and specificity suffers from 
batch-to-batch variation [126].  
 
Table 1.3 Polyclonal antibody comparison with monoclonal antibody [126]. 
Polyclonal antibody Monoclonal antibody 
Animal (e.g. mouse) needs to be immunised with specific antigen 
Purified from serum B cells from immunised animal are fused 
with myeloma cell to form hybridoma  
Technology and skills required are low Technology and skills required are intensive 
Time period is relatively short Time period is long due to hybridoma work 
Recognise multiple epitopes of specific 
antigen 
Only binds to one epitope on antigen 
Each lot differs Hybridoma secreting the same antibody, and 







1.5.2 Monoclonal antibodies  
In 1975, Kohler and Milstein developed mouse monoclonal antibodies [113]. They used B 
cell to hybridise with immortalized myeloma to form a new cell, called a hybridoma. A 
hybridoma retains the ability of the B cells by secreting specific monoclonal antibody, but 
has an infinite lifespan owing to the myeloma cell [113]. It is a milestone for antibody 
production (Fig 1.5). Monoclonal antibodies are good tools for scientific research [129] and 
more importantly, they can be used in immunotherapy, such as murine monoclonal antibody 
to CD3 had been approved by the US Food and Drug Administration in order to treat acute 
transplant rejection [130]. Since then, this technology has been widely used, and antibodies 
are being developed to serve as new therapies for the treatment of cancer, autoimmunity and 
inflammatory diseases [131] are ongoing. Monoclonal antibodies have many advantages over 
polyclonal antibodies. Table 1.3 summarises the differences between polyclonal and 
monoclonal antibodies.  
A downside to injected murine monoclonal antibodies is that it could induce self-antibody 
production (autoantibodies) in a bid to neutralize or eliminate the therapeutic antibodies [132, 
133]. Subsequently, human monoclonal antibody to Epstein-Barr virus (EBV) was then 
developed, but the production quality is low [134, 135]. Human antibody production in 
animals using TransChromo (TC) technology was  developed, where a human chromosome 
fragment (HCF) as a vector containing human DNA was integrated into the genome of TC 
mouse™ [136]. In this way, the chance for self-antibody production against therapeutic 
antibody is greatly reduced. Such mice then rearrange human immunoglobulin genes and 






Figure 1.5 A typical monoclonal antibody production flow. This figure is adapted from 
[137]. Polyclonal antibodies can be harvested from immunized host (such as mouse), 
alternatively, antibody-forming cells can be fused with tumour cells to form hybridomas in 
order to secrete monoclonal antibody [137].  
 
1.5.3 Recombinant antibodies  
In 1973-1974, recombinant DNA technology has been developed [138]. The first licensed 
drug generated by this technology was insulin [139]. Antibody fragments were also 
developed using recombinant DNA technology, particularly the recombinant fragment 
antigen binding regions (Fab) [115] and single chain variable fragment (scFv) [140] are 
expressed in E. Coli and those fragments became popular antibody fragments generated with 
this technology. Both antibody fragments have been successfully produced and assayed. Due 
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to antigen binding regions of an antibody in heavy and light chain variable regions, and the 
complementarity determining regions (CDRs) from both chains determine the specificity of 
the antibody. The murine CDRs could be inserted  into human antibody framework to replace 
its CDRs and form a humanised antibody to recognise the desired antigens [141]. In addition, 
antibodies could also be expressed intracellularly using mammalian cells [142]. More 
recently, a novel tool for rapid cloning and expression of recombinant antibodies has been 
investigated and developed [143]. The antibody heavy and light chains are assembled in a 
one-step process by cloning them into a single mammalian expression vector. The antibody 
was then expressed via DNA encoding the specific variable and constant regions rapidly. It 
increased confidence of in vitro antibody production [143].  
To further improve the process, knowing the peptide sequence of the specific antibody is 
crucial. Moreover, researchers could use the same condition and peptide sequence to produce 
the heterogeneous binding antibodies [129]. Therefore, a novel proteomic approach to 
produce a recombinant monoclonal antibody has recently been developed in 2012 [144]. 
Briefly, polyclonal antibodies from an immunized rabbit were purified by chromatography, 
digested with multiple enzymes and mapped using tandem mass spectrometry (MS/MS). The 
determined CDRs especially CDR3 have been screened and assumed to be a high affinity and 
specificity antibody. This antibody was then expressed and secreted in vitro [144]. This 
technology has been lauded for furthering recombinant monoclonal antibody production.  
 
1.5.4 Phage display 
The process of antibody variable fragments successfully displayed on the phage surface by 
inserting  antibody coding DNA sequence into phage genomes [116], is called phage display 
[145]. In general, phage display uses recombinant DNA technology to replicate DNAs 
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encoding desired polypeptides [145]. In the same way, cDNA coding human antibody heavy 
and light chain variable regions are from the V gene repertoires of lymphocytes and 
expressed on the surface of filamentous bacteriophage [146]. The displayed antibodies are 
specific for a particular antigen, which can be isolated with biopanning [147]. 
 
1.5.5 mRNA and DNA display  
RNA display is a type of technique that creates a library of fusion products of coding RNAs 
or DNAs and their corresponding polypeptides generated by nucleotide synthesis and in vitro 
translation systems [148, 149]. Using target antigen, the polypeptides that have strong 
binding affinity to the antigen can be pulled down and the fused RNA or DNA coding 
sequence for the polypeptides will be recovered and used for expressing the polypeptide in a 
large scale using designated expression system [150].  




Figure 1.6 Overview of RNA display. This figure is adapted from reference [149] and 
advance developed in reference [151]. 
 
This technique has advanced the phage display and is more effective and straight forward in 
screening polypeptides that bind to specific antigens [152]. However, this is not suitable for 
antibody screening because antibody is a large and complicated molecule composed of two 
heavy and two light chains.  
 
1.6 Mass spectrometry approaches 
The principle of mass spectrometry (MS) is used for measuring the mass or the mass-to-
charge ratio (m/z), including the ionization source, the mass analyser and the detector. 
Performing single and tandem mass spectrometry are two classes of proteomics [153]. Mass 
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spectrometry is a powerful tool for proteomic applications including sample approaches and 
bioinformatics tools (e.g. PEAKS) for data analysis [154]. On the other hand, mass 
spectrometry can also study human diseases and translate to the clinical setting and as such 
identity potential biomarkers [155]. 
Tandem mass spectrometry (MS/MS) has become an increasingly reliable tool to identify 
proteins, because the mass of the fragmented peptides could be measured [156]. MS is widely 
used to characterize proteins in order to investigate the process of cell biology, especially for 
protein identification [157]. The purified proteins are normal separated using sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), as well as two dimensional gel 
electrophoresis, which can separate proteins according to their molecular weight or isoelectric 
point (PI). The bands or spots are cut into slices and digested with specific enzyme (e.g. 
Trypsin), known as in gel digestion [158]. The digested proteins are normally paired with 
liquid chromatography MS/MS (LC-MS/MS) [158] (Fig. 1.7). For MS spectra data analysis 
after MS/MS, there are several approaches to search databases using genomes with the 
uninterpreted experimental MS/MS data, such as Mascot [159] and Sequest [160]. However, 
these software could give a false or incorrect identification [161]. Effective software for 
spectra analysis has been designed, known as PEAKS. This novel approach has multiple 
functions including de novo sequence, post-translational modification and SPIDER, which 
can easily align the peptide sequence [161, 162].  
This method is ideal for isolating human antibodies and reproducing them by recombinant 
DNA technology. In chapter 3 and 4, MS/MS was used to identify the antibodies peptide 







Figure 1.7 Overview of LC-MS/MS. This figure is adapted from reference [163]. Proteins 
can be digested by enzymes such as trypsin to form peptides. Peptides are further investigated 
in LC-MS/MS in order to acquire the raw mass spectrum. Each single peak is selected and 




Chapter 2 Production of Mouse Anti-Histone and Humanized Anti-Histone Antibody 
Fragments to Block Histone Toxicity 
 
2.1 Introduction 
Currently, there are no commercial anti-histone antibodies available for in vivo interventions. 
Much of our research work requires in vivo experiments with a large quantity of anti-histone 
antibodies [14, 48]. Moreover, circulating histones play important pathological roles in many 
critical illnesses, such as severe trauma, sepsis and necrotizing pancreatitis and as such anti-
histone therapy is needed [48]. Clinically, a humanised anti-histone antibody has great 
potential to be used as a major anti-histone reagent. In this chapter, I first produced a 
MahscFv and tested its function in reducing histone toxicity. Then, I generated a humanised 
anti-histone scFv (HahscFv) by transferring the CDRs from the MahscFv to a human scFv. In 
addition, the MahscFv was conjugated with Fc fragments in order to enhance the clearance of 
antigen-antibody complexes by macrophages in vivo and the effectiveness tested in mice. For 










2.2 Methods  
 
2.2.1 Competent bacteria preparation with Rubidium Chloride 
Rubidium Chloride was used in the production of competent E. coli. Bacteria were cultured 
in 100 mL Luria-Bertani (LB) broth (Sigma, USA) to reach an optical density (OD) of 0.5 at 
absorbance 600 nm. Incubated broth was chilled on ice for 15 min, before centrifugation at 
4,000 × g, 4 °C for 10 min. The resultant pellet was resuspended in 35 mL of ice cold RF1 
(100 mM RbCl, 50 mM MnCl2, 30 mM KAc, 10 mM CaCl2, 15% (v/v) Glycerol, pH 5.8) and 
incubated for 15 min on ice. The resuspended pellet was then centrifuged again as mentioned 
above. The pellet was next resuspended in 8 mL ice cold RF2 (10 mM MOPS, 10 mM RbCl, 
75 mM CaCl2, 15% (v/v) Glycerol, pH6.8) and incubated for 15 min. 100 µL aliquots of the 
bacterial suspension were retained and stored at – 80 °C.  
 
2.2.2 Bacterial transformation with plasmids 
Bacterial heat-shock transformation was employed as previously describe [164]. Plasmid 
amplification was performed using Subcloning Efficiency™ DH5α™ Chemically Competent 
Cells E. coli (Invitrogen, USA). 2 µL of plasmid (the plasmid construction will be mentioned 
in section 2.2.7) was added to 50 µL of DH5α E. coli and incubated on ice for 20 min, 
followed by 45 s at 42 °C in water bath for the heat-shock step. DH5α were immediately 
transferred on ice. Next, 250 µL of LB broth was added and the mixture incubated at 37 °C 
for 45 – 60 min. After incubation, transformed DH5α E. coli were harvested at 6,000 × g for 
5 min. The resultant pellet was then spread on an agar plate containing 100 µg/mL ampicillin 




2.2.3 Plasmid amplification 
Following the manufacturer’s protocol, a single colony of DH5α E. coli containing plasmid 
was selected and incubated in 6 mL LB broth containing 100 µg/mL ampicillin for 16 h at 
37 °C and 180 rpm. After incubation, the DH5α E. coli suspension was centrifuged at 3,000 × 
g for 20 min. The harvested pellet was dried at room temperature for 20 min and resuspended 
with 250 µL buffer P1 (QIAprep Spin Miniprep Kit, QIAGEN) and transferred to a 1.5 mL 
Eppendorf. 250 µL of buffer P2 was then added to the cell lysis for no more than 5 min. 350 
µL of buffer P3 was then added to neutralise the solution and centrifuged at 16,000 × g for 15 
min. The supernatant containing the plasmid was then applied to a QIAprep spin column for 
1 min and centrifuged for 1 min. 500 µL of buffer PB was added and incubated for 1 min and 
centrifuged. The column was then washed with 750 µL of buffer PE for 1 min and 
centrifuged. DNA was finally eluted with 50 µL of H2O.  
 
2.2.4 Restriction enzyme digestion and agarose gel electrophoresis  
After plasmid elution using QIAprep Spin Miniprep Kit, 10 µL of plasmid was digested by 
restriction enzymes NdeI (NEB, USA) and BamHI (NEB, USA) at 37°C for 1 h. The 
digested DNA and 1 µL 2-log DNA Ladder (0.1-10.0 kb) (NEB, USA) were analysed by gel 
electrophoresis on a 1% (w/v) agarose gel. Images were taken under a UV light.  
 
2.2.5 Large-scale plasmid amplification 
Large-scale plasmid amplification was performed using a Midiprep Kit (Qiagen, 
Netherlands), as in the manufacturer’s instruction. A single colony of DH5α E. coli was 
selected and grown in 5 mL of LB broth containing 100 µg/mL ampicillin at 37 °C for 8 h. 
This was then transferred to 100 mL of LB and grown for 16 h under the same conditions. 
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The DH5α E. coli were then harvested at 6,000 × g for 15 min at 4 °C, and the pellet 
resuspended with 4 mL of buffer P1. Cells were lysed with 4 mL of buffer P2 for 5 min, 
followed by neutralisation with 4 mL of buffer P4, before incubating the mixture on ice for 
15 min. The resulting mixture was centrifuged at 20,000 × g for 30 min at 4 °C and the 
supernatant applied to a pre-equilibrated (with 4 mL of buffer QBT) QIAGEN-tip 100 
column. Next, the column was washed with 10 mL of buffer QC twice. The DNA was eluted 
with 5 mL of buffer QF, precipitated by 3.5 mL isopropanol and centrifuged at 26,891 × g for 
30 min at 4 °C. The DNA pellet was then washed with 2 mL of room-temperature 70% (v/v) 
ethanol and centrifuged for 10 min. The DNA pellet was then air-dried before resuspension 
with 200 µL H2O. 
 
2.2.6 DNA extraction using QIAquick Gel Extraction Kit (QIAGEN, Netherlands) 
30 µL of purified Plasmid from the Midiprep above was digested with restriction enzymes 
NdeI (NEB, USA) and BamHI (NEB, USA) for 1 h at 37 °C. After digestion, DNA 
fragments were then separated by gel electrophoresis using 1% (w/v) Tris borate EDTA 
(TBE) agarose. After electrophoresis, the DNA band was isolated under UV light and placed 
in a universal tube. The gel was then extracted using a QIAquick Gel Extraction Kit. Briefly, 
three times the gel weight of buffer QG was added and heated at 50 °C for 10 min until no 
agarose gel pieces were left. An equal volume of isopropanol to gel weight was added and 
subsequently mixed. 750 µL of the mixture was then loaded onto a QIAquick column to bind 
DNA and centrifuged until all the solution was applied. 500 µL of buffer QG was added to 
column in order to remove all trace of agarose gel. The column was then washed with 750 µL 




2.2.7 Ligation  
To express the above proteins in E. coli, the pET-16b vector (Novagen, Germany) was used 
to ligate the coding DNAs including MahscFv, HahscFv, HahscFv-Fc and control scFv 
(CscFv). The pET-16b vector containing T7 expression system was digested with NdeI and 
BamHI and extracted using a QIAquick Gel Extraction Kit. Coding sequences for MahscFv 
were synthesized by GENEWIZ (USA), HahscFv and CscFv were synthesised by Life 
techonologies (Waltham, USA) with NdeI and BamhI restriction sites on 5’ and 3’ ends, 
respectively. The plasmids containing these coding sequences from the company were also 
digested with NdeI and BamHI restriction enzymes and the DNA fragments containing these 
coding sequences were separated from its vector using agarose gel electrophoresis and 
extracted using QIAquick Gel Extraction Kit. 4 µL of pET-16b vector and 12 µL of an insert 
(coding DNA) were mixed with 2 µL of T4 ligase buffer and 2 µL T4 ligase (NEB, USA) 
each, and incubated at room temperature for 1 h. After ligation, 5 µL ligation mixture was 
then transformed to DH5α competent cells E. coli and incubated on an LB agar plate 
containing 100 µg/mL ampicillin at 37 °C overnight.  
   
2.2.8 DNA sequencing  
To confirm that the DNA sequences were correct, the purified plasmids were sequenced by 
Beckman Coulter Genomics (Takeley, UK). 
 
2.2.9 Protein induction  
2 µL of plasmid was transformed into C41 (DE3) E. coli. The following day, single colonies 
were selected and each incubated in 3 mL LB broth containing 100 µg/mL (w/v) ampicillin 
for 1 h at 37°C. Bacteria were then induced at 37°C for 4 h with 1 mM IPTG (Melford, UK), 
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with a non-induced colony acting as negative control. After incubation, 1 mL of bacteria was 
centrifuged at 16,000 × g for 30 s. The pellet was re-suspended with 100 µL H2O, then 20 µL 
of the cell lysate was analysed by 15% SDS-PAGE. Once the small scales induction was 
successful, a large scale induction was conducted. Bacteria were continually incubated in 500 
mL LB broth containing 100 µg/mL ampicillin at 37°C and the bacteria optical density 
(OD600) measured at 600 nm until reaching an OD reading of between 0.5 and 0.6. The 
bacteria were subsequently induced at 37°C for 4 h. The non-induced and induced bacteria 
were then run on a 15% SDS-PAGE. 
 
2.2.10 Protein purification using a Nickel-Nitrilotriacetic acid (Ni-NTA) resin 
(QIAGEN, USA) column 
After large scale induction, bacteria were harvested at 6,000 × g for 10 min at 4 °C. The 
pellet was resuspended in lysis buffer (50 mM Tris-HCl, pH7.4, 500 mM NaCl), and 
sonicated for 3 min with a rest period of 3 min on ice and repeated twice. The supernatant 
was then acquired through centrifugation at 26,981 × g for 30 min at 4 °C. The remaining 
pellet was resuspeneded with denaturation buffer (8 M urea, 50 mM Tris-HCl, pH7.4, 500 
mM NaCl) and the sonication repeated. In order to identify the MahscFv, each supernatant 
was run on a 15% SDS-PAGE. For the native purification step, the MahscFv supernatant was 
applied to a Ni-NTA resin (QIAGEN, USA) column and washed with wash buffer (50 mM 
Tris-HCl, pH7.4, 500 mM NaCl, 50 mM Imidazole). MahscFv was eluted with native elution 
buffer (50 mM Tris-HCl, pH7.4, 500 mM NaCl, 250 mM Imidazole), and dialysed against 
PBS, exchanging the buffer twice in cold room. For MahscFv denaturation purification, the 
denatured inclusion bodies are also applied to a Ni-NTA resin (QIAGEN, USA) column, 
washed with denaturation wash buffer (8 M urea, 50 mM Tris-HCl, pH7.4, 500 mM NaCl, 50 
mM Imidazole) and eluted with denaturation elution buffer (8 M urea, 50 mM Tris-HCl, 
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pH7.4, 500 mM NaCl, 250 mM Imidazole). The denatured MahscFv is refolded against a 
gradient urea concentration (4, 2, 1, and 0.5 M urea) using dialysis, and the buffer finally 
exchanged with PBS. 
 
2.2.11 SDS-PAGE and Coomassie brilliant blue staining 
Proteins were loaded into 10 – 15% SDS-PAGE and subjected to electrophoresis at 30 
mAMP/gel for 1 h. Following electrophoresis, the gels were stained using Coomassie brilliant 
blue staining buffer containing 0.25% (w/v) Coomassie brilliant blue, 10 % (v/v) acetic acid 
and 30% (v/v) methanol for 30 min at room temperature, as described in [165]. After 
staining, the gel was destained with 10% (v/v) acetic acid and 30% (v/v) methanol for 6 
hours, changing the destaining buffer four times. 
 
2.2.12 Antibody conjugation to peroxidase  
100 µL of ultra-pure H2O and ~1 mg of purified antibody was added into EZ-Link™ Plus 
Activated Peroxidase (Thermo Fisher, USA), 10 µL of Sodium cyanoborohydride solution 
(Sigma, USA) was also mixed with the solution and incubated at room temperature for 1 h. 
After incubation, 20 µL Ethanolamine was added and incubated for 15 min at room 
temperature. Following conjugation of MahscFv-HRP, the solution was stored at 4°C for up 
to two weeks to preserve the activity. 
 
2.2.13 Western blotting 
2 µg of recombinant histone H1, H2A, H2B, H3 and H4, 10 µg of calf thymus histone and 5 
µg of S100P (negative control) were loaded onto a 15% SDS-PAGE and run at 30 mAMP/gel 
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for 1 h, then transferred onto a 0.45 µm Immobilon®-P PVDF Membrane (Millipore, USA) 
at 400 mAmp for 1 h. The membrane was then blocked with 25 mL of blocking reagent 5% 
(w/v) Instant dried skimmed milk (Tesco, UK) and 2% (w/v) Bovine Serum Albumin (BSA) 
(Sigma, USA) suspending in Tris buffer saline Tween-20 (TBS-T) for 1 h at room 
temperature. The membrane was then incubated with MahscFv-HRP (1:500) (v/v) in block 
reagent for 1 h at room temperature, the membrane was also incubated with 5 µg/mL of HRP 
only as a control. After incubation, the membrane was washed 3 × with TBS-T and the 
MahscFv-HRP signals evaluated by Immobilon™ Western Chemiluminescent HRP Substrate 
(Millipore, USA) for 3 min at room temperature. Images were acquired using G:Box gel 
imaging system (Syngene, India) and software GeneSnap (Syngene, India). Alternatively, 
after membrane blocking, mouse primary antibody IgG was incubated using the same 
reagents for 16 h at 4°C, and subsequently anti-mouse IgG-HRP secondary antibody 
(1:10,000) was incubated with membrane for 1 h at room temperature (RT). The image was 
acquired using chemiluminiscent detection with G box gel imaging system (Syngene) and 
software GeneSnap (Syngene).  
 
2.2.14 Protein concentration determination using Bradford assay and NanoDrop 
Bradford assay, the concentration of purified proteins was tested using a DC™ Protein Assay 
(Bio-Rad, USA) and the Quick Start™ BSA standard set (Bio-Rad, USA) referring to the 
instruction manual. Briefly, 5 µL of standards and samples were loaded into a 96-well-plate 
and 25 µL of a mixture of reagents S and A (20 µL reagent S and 1 mL reagent A) were 
added into each well. 200 µL reagent B was finally added to each well, and incubated at room 
temperature for 15 min. The absorbance of the samples was read at 750 nm absorbance and 
the protein concentrations calculated using BSA standard curve.  
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Nanodrop, Protein concentration calculation have been described in details using nanodrop 
[166]. Here, the Nanodrop ND-1000 Spectrophotometer (USA) was used for calculation of 
antibody concentrations using OD readings at 280 nm. 2 µL of H2O was initially applied to 
the nanodrop, and the 2 µL of PBS was used as a blank. The protein concentrations were 
calculated using the mass extinction coefficient number (each protein has a unique coefficient 
number). 
 
2.2.15 Functional assay 
Cell death was investigated by staining damaged nuclei with propidium iodide (PI) [167]. 
Briefly, EA.hy926 cells (endothelial cells) were cultured at 37 °C and 5% CO2 in T75 Flask 
to reach 90-100% confluence. Cells were washed twice with 10 mL of PBS and detached 
with 2 mL of versene solution (Life technologies, USA) for 10 min at 37 °C and 5% CO2, 
and neutralised with 10 mL of advanced Dulbecco’s modified eagle medium (DMEM) (Life 
technologies, USA) containing 20% (v/v) Fetal bovine serum (FBS) (Sigma, USA), 1% (v/v) 
penicillin-streptomycin (Pen Strep) (Invitrogen, USA), 1% (v/v) L-Glutamine 200 mM 
(Invitrogen, USA). The cell suspension was then centrifuged at 500 × g for 5 min. The cell 
pellet was resuspended with 24 mL media and 1 mL aliquoted in each well of 24-well-plate, 
and incubated at 37 °C under 5% CO2 overnight. Cell confluence was examined the 
following day by microscopy. The cells were then washed twice with PBS and 200 µL of 
treatment was then added into each well and incubated at 37 °C under 5% CO2 for 1 h. 10 
µg/mL of PI solution (Sigma, USA) was added into each well and incubated for 10 min under 
same conditions. After incubation, cells were detached with 40 µL of versene and washed 
with PBS twice by centrifugation at 500 × g for 5 min. Cells were finally resuspended into 
200 µL of PBS and analysed using the BD FACSCalibur (USA) with the untreated controls 
designated as 100% viable and cell survival rates normalized thereafter.  
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The viability of EA.hy926 cells were also assessed by water-soluble tetrazolium salt (WST-8) 
cell proliferation assay kit (Enzo Life Sciences). 1.5 × 10
4
 cells were cultured in a 96-well-
plate using the same condition as above, until reaching 100% confluence. Firstly, cells were 
treated with a series of concentration of calf thymus histones (20, 30, 50, 100, 200 and 300 
µg/mL) within 100 µL fresh media for 1 h, and washed by PBS twice. 10 µL of WST-8 dye 
was mixed with 100 µL fresh medium and incubated for 1 h. The absorbance (at a 
wavelength of 150 nm and a reference wavelength of 650 nm) of each well was finally 
measured using a plate reader (Multiskan Spectrum, Thermo Fisher Scientific). Cells were 
secondly treated with various concentrations of antibody (20, 50, 100, 200 and 300 µg/mL) 
for 5 min and subsequently treated with 250 µg/mL of calf thymus histones for 1 h. The 
measurement method was the same as above.  
The assay for cardiomyocyte viability has been described in Dr Y. Alhamdi’s publication 
[37]. Briefly, murine HL-1 cells (adult cardiomyocytes) [168, 169] were from Professor 
William Claycomb (Louisiana State University, USA) and cultured in Claycomb medium 
including 10% (v/v) FBS, 2 mM L-Glutamine, 100 U/mL Penicillin/Streptomycin and 100 
µM Norepinephrin [169]. Cells were treated with 50 µL fully supplemented Claycomb media 
and 50 µL Septic patient’s Sera to a 100 µL mixture into each well of 96-well-plate. 
Alternatively, 50 μg/mL of antibody was pre-treated with the HL-1 cells and septic sera were 
subsequently added. Cell viability was measured by WST-8 described as above.  
 
2.2.16 MahscFv-Fc production  
In order to eliminate any MahscFv-histone complexes in the circulating system during in vivo 
experiments and to demonstrate the solubility, MahscFv was ligated to a mouse Fc fragment 
from IgG1 [170]. This involved the design of a restriction site at each mouse Fc terminus 
41 
 
(NcoI and NdeI, respectively). The synthesised mouse Fc DNA was then digested with NcoI 
(NEB, USA) and NdeI, as well as the MahscFv plasmid (within pET-16b vector). The 
digested mouse Fc and MashcFv were ligated using T4 ligase buffer and T4 ligase (NEB, 
USA) to form a new plasmid MahscFv-Fc. The MahscFv-Fc was finally expressed in 
competent E. Coli BL21 (DE3) and purified using on-column refolding.  
 
2.2.17 Binding assay using enzyme-linked immunosorbent assay (ELISA) 
In order to investigate the binding between MahscFv and histones, two ELISA methods were 
developed. Method one involved 100 µL of ELISA coating buffer (50 mM Na2CO3, 50 mM 
NaHCO3, pH9.6) containing 10 µg/mL of recombinant histones (H1, H2A, H2B, H3 and H4) 
which were individually coated onto a 96-well-plate overnight at 4°C. The next day, the plate 
was washed twice with PBS-T (PBS + 0.05% (v/v) Tween20), blocked with 5% (w/v) 
skimmed milk, 2% (w/v) BSA for 1 h and washed four times with PBS-T. The plate was then 
incubated with MahscFv-HRP (1:500) (v/v) containing PBS-T for 1 h at room temperature 
and then washed four times again. The MahscFv-HRP signal was assessed by 3,3,5,5-
Tetramethylbenzidine (TMB) Substrate Reagent Set (BD,USA), and measured the 
absorbance at 450 nm. Method two utilized the fact that histones binding to streptavidin 
[171], whereby, 100 µL of 10 µg/mL MahscFv suspended within ELISA coating buffer was 
coated onto a 96-well-plate overnight at 4 °C. After washing and blocking the plate, various 
concentration of recombinant Histones were incubated for 1 h, and the washed plate then 
incubated with streptavidin-HRP for 30 min. The optimal density (OD) 450nm reading was 




2.2.18 Animal experiments 
Animal experiments were performed in China by Southeast University who holds the 
appropriate ethical approval. The full details of in mice experiments are described in Dr Yasir 

















2.3 Results   
2.3.1 Diagrams of MahscFv, CscFv, MahscFv-Fc and HahscFv 
Figure 2.1 shows schematic diagrams of mouse anti-histone scFv (MahscFv), control scFv 
(cscFv), MahscFv-Fc and humanised anti-histone scFv (HahscFv).  
 
 
Figure 2.1 Schematic diagrams of MahscFv, CscFv, MahscFv-Fc and HahscFv. (A) 
Mouse anti-histone variable heavy and light chains were linked by a flexible linker (B) 
control scFv. (C) The MahcFv was linked to mouse IgG1-Fc fragment to form MahcFv-Fc. 
(D) CDRs of the MahscFv were used to replace CDRs of a human heavy and light chains to 




2.3.2 Plasmids construction and proliferation  
For plasmid construction and proliferation, a pET expression system was used [172]. scFvs 
were subcloned into pET-16b vector in an expression system that contains a T7 promoter and 
ampicillin resistant marker, as well as a His10-tag. To ensure that the MahscFv DNA was 
successfully ligated to the pET-16b vector, the scFvs and pET-16b DNA were sequenced by 
SnapGene
®











Figure 2.2 Plasmids for scFv expression. (A) MahscFv DNA was digested with BamHI and 
NdeI and ligated to pET-16b vector to form a novel plasmid of MahscFv-pET-16b (6,408 
bp). Plasmid of the MahscFv was digested by BamHI and NdeI, and subjected on 1 % (w/v) 
agarose gel and showed a correct 702 bp band. (B) The designed CscFv DNA fragment was 
ligated into pET-16b vector using NdeI and BamHI restriction sites to form CscFv-pET-16b 
plasmid (6,477 bp) which was verified on a 1% (w/v) agarose gel using NdeI and BamHI 
digestion to achieve a correct 771 bp band. (C) Mouse IgG1 Fc DNA fragment (711 bp) 
including CH2 and CH3 was ligated to the plasmid of MahcFv-pET-16b using NcoI and NdeI 
restriction sites to form a new plasmid of MahscFv-Fc-pET-16b (7,071 bp) which was 
examined in a 1% (w/v) agarose gel using NcoI and BamHI digestion and showed the correct  
1,425 bp band. (D) The same procedure was used to ligate the HahscFv to pET-16b to form 
HahscFv-pET-16b (6,447 bp) which was digested with NdeI and BamHI enzymes to 
achieved a correct 741 bp band on agarose gel. All plasmids were sequenced and no point 











2.3.3 Protein induction and purification  
The expression plasmids were transformed into BL21 (DE3) E. coli for protein expression. 
The correct molecular weight band could be observed in induced E.coli which was not 
apparent in the non-induced E. coli (Fig 2.3A left). The MahscFv was then purified by Ni-
NTA resin, refolded with decreasing concentration of urea and separated by 15% SDS-PAGE 
and stained with Coomassie brilliant blue (Fig. 2.3A right). Using the same method, CscFv 
(29.7 kDa) was also induced in BL21 (DE3) E. coli (Fig. 2.3B left), and purified and 
examined on a 15% SDS-PAGE (Fig 2.3B right). Accordingly, the MahscFv-Fc (52.2 kDa) 
(Fig. 2.3C) and HahscFv (28.5 kDa) (Fig. 2.3D) were successfully produced in the DE strain. 
Following purification, all scFv proteins had a purity of greater than 90%. 
 
 
Figure 2.3 Antibody induction and purification. (A) MahscFv expression plasmid was 
transformed using BL21 E. coli and then induced at 30°C with 1 mM IPTG. The non-induced 
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E. coli was used as negative control. The induced band was 27 kDa which is matched with 
the calculated molecular weight. The MahscFv was insoluble and the inclusion bodies were 
denatured in Urea and refolded on Ni-NTA resin column. The purity of MahscFv was 
determined using SDS-PAGE and Coomassie brilliant blue staining and found to be greater 
than 90%. (B) CscFv, (C) MahscFv and (D) HahscFv were produced using the same 
procedure as above.  
 
2.3.4 Binding analysis 
To investigate whether these scFvs are specific to histones, recombinant histone H1, H2A, 
H2B, H3, H4, calf thymus histones and S100P (negative control) were run on a 15% SDS-
PAGE and stained with Coomassie brilliant blue, in order to confirm the presence of each 
protein (Fig. 2.4A). The same amount of each protein was then loaded into a new gel and 
transferred to PVDF membrane and probed with MahscFv-HRP. Under reducing conditions 
the MahscFv bound to each recombinant histone, including calf thymus histones, but not 
S100P (Fig. 2.4B), whereas no band was found using the same proteins but probed with HRP 
alone (data not show). The same method was used to demonstrate the specificity of MahscFv-
Fc. (Fig. 2.4C) and HahscFv (Fig. 2.4D). In contrast, CscFv-HRP did not bind to either 







Figure 2.4 Specificity of recombinant scFvs (A) 2 µg of recombinant histones H1.0, H2A, 
H2B, H3.1, H4, calf thymus histone and S100P were subjected to 15% SDS-PAGE. (B) The 
proteins were also transferred to PVDF membrane and probed with MahscFv-HRP, (C) 
MahscFv-Fc-HRP, (D) HascFv-HRP, or (E) CscFv-HRP.  
 
To examine binding of HahscFv to histones under physiological conditions, the HahscFv was 
coated onto a 96 well plate and an ELISA was performed.  Binding was determined using 
various concentrations of histones and streptavidin-HRP was used as a detector, since 
streptavidin can directly bind to histones [171]. The same concentrations of human histones 
H1, H2A and H2B were used, where by maximum binding at was seen at 100 nM histones. 
However, in this assay H1 showed a relatively low binding response compared to both H2A 
and H2B (Fig. 2.5A). In contrast, H3 and H4 required a much higher concentration to bind to 
the HahscFv, with maximal binding at 800 nM histones (Fig. 2.5B).  
To determine the binding affinity of scFvs to histones, a surface plasmon resonance (SPR) 
system was used. Calf thymus histones were captured on sensor chip streptavidin (SA), and 
histone binding affinity to increasing concentrations (0.1, 0.3, 0.5, 0.8, 1.0, 1.5, 2.0 and 3.0 
µM) of MahscFv, MahscFv-Fc and HahscFv, was determined. Following the Biacore™ X100 
measurement, the affinity of MahscFv to Histones was determined to be 1.327 × 10
-6
 M (Fig. 
2.6A), MahscFv-Fc to histones affinity was 2.045 × 10
-6
 M (Fig. 2.6B), and HahscFv to 
histones affinity was 3.529 × 10
-6
 M (Fig. 2.6C).  
Taken together, these data demonstrate that all individual histones bound to HahscFv under 






Figure 2.5 Binding of HahscFv to histones using ELISA. Binding of humanised ahscFv 
(HahscFv) to individual histones was determined by ELISA. (A) HahscFv was coated on a 96 
well plate, and a series of concentration (1, 10, 20, 40, 100 and 200 nM) of H1, H2A and 
H2B were added and incubated for 3 hours.  After extensive washing, streptavidin-HRP was 
added for 1 hour. (B) Following the same procedure as in (A), histone H3 and H4 binding to 
HahscFv was determined using increasing histone concentrations (50, 100, 200, 400, 600, 








Figure 2.6 Affinities of scFvs to calf thymus histones. (A) Calf thymus histones were 
captured on sensor SA chip, and a series of MahscFv antibody concentrations (0.1, 0.3, 0.5, 
0.8, 1.0, 1.5, 2.0 and 3.0 µM) were added. The affinity between MahscFv and histones was 
1.327 × 10
-6
 M, (B) the affinity of MahscFv to histones was 2.045 × 10
-6
 M, and (C) HahscFv 




2.3.5 MahscFv inhibits histone-induced endothelial and cardiomyocyte cells toxicity in 
vitro  
Since 2009, extracellular histones have been reported to be toxic to endothelial cells [14], 
which has further been characterized by our group [91]. In my experiments, EAhy926 cells 
(endothelial-like cells) [91] were treated with 50 µg/mL calf thymus histones, which showed 
significant toxicity to endothelial cells, compared with untreated cells, and this toxicity was 
significantly reduced by 100 µg/mL of MahscFv (Fig. 2.7A). To further demonstrate the 
protective effect of MahscFv and to investigate the possible translational relevance of this 
anti-histone treatment, HL-1 cells (cardiomyocytes) were treated with serum from septic 
patients. The serum from patients with circulating histone levels > 75 µg/mL was 
significantly toxic towards cardiomyocytes compared to normal serum and septic patient 
serum with histone levels < 75 µg/mL.  Furthermore, this toxicity could be abrogated by 50 
µg/mL of MahscFv (Fig. 2.7B). These data demonstrate that the major toxic effect within this 
patient serum was attributed to histones, and that this could be inhibited by MahscFv.  In 





Figure 2.7 MahscFv protection against histone-induced endothelial and cardiomyocyte 
cell toxicity. (A) EAhy926 (Endothelial-like) cells were incubated in 2% FCS with or 
without 50µg/mL calf thymus histones, pre-incubated without or with 100 µg/mL MahscFv 
for one hour. Cells were stained with propidium iodide (PI) (10µg/mL) prior to flow 
cytometric analysis. The untreated (UT) cells were set as 100% (*p < 0.05 compared with 
untreated cell #p < 0.05 compared with histones treated cells n = 4). (B) HL-1 
(cardiomyocytes) were treated with normal serum, septic serum (histones level < 75 µg/mL), 
septic serum (histones level > 75 µg/mL) and septic serum (histones level > 75 µg/mL) + 50 
µg/mL MahscFv. The cell viability was measured by WST-8 assay. Cell survival of cells 
treated with normal serum was fixed as 100%. *p < 0.05 was compared with normal serum 
and #p < 0.05 compared with septic serum (histones level > 75 µg/mL). This figure had been 






2.3.6 MahscFv abrogates cardiac injury in septic mice 
Calf thymus histones infusion in mice had been tested in mice leading to lethality, and 
coinfusion of 10 mg/kg MahscFv had successfully rescued mice of which the mice had 
injected with a lethal-dose of histones [48].  
To further characterize the protective effect MahscFv in vivo, septic mice were used.  
Induction of murine sepsis using intraperitoneal E.coli injection (1 × 10
8
 CFU/mL) showed 
significantly elevated levels of circulating cardiac Troponin I (cTnI), a well-known clinical 
marker of cardiac injury, indicating cardiac injury in these septic mice. Furthermore, the 
levels of circulating cTnI were significantly correlated with circulating histone levels (data 
not shown) [37].  Taken together, this suggests that elevated circulating histones may play a 
role in inducing cardiac injury in these mice.  To test this hypothesis MahscFv was infused 
into septic mice (8 and 16 hours after sepsis induction) and circulating cTnI was quantified.  
In fact, MahscFv infusion into septic mice significantly reduced cTnI levels, suggesting that 
histones play a role in cardiac injury and dysfunction during sepsis, which can be protected 





Figure 2.8 MahscFv protection of histone induced cardiac injury in mice. Cardiac 
troponin I (cTnI) levels shown in Sham mice (n = 6), septic mice (n = 6) and septic mice + 10 
mg/kg MahscFv intervention (n = 6). Data is expressed as mean +/- S.D; *p < 0.05 when 
compared with Sham and #p < 0.05 compared with sepsis mice. This figure had been 
presented in reference [37].  
 
2.3.7 Detoxifying histones in vitro with MahscFv-Fc 
The MahscFv had been used to successfully reduce histone-induced cytotoxicity in vitro, and 
rescued mice in in vivo and is further characterized in this chapter. Therefore, I wanted to 
investigate the protective role of the novel mouse anti-histone scFv, used in this thesis, which 
is linked with Fc fragments from mouse IgG1 antibody.  I have currently demonstrated that 
this antibody retains its specificity towards histones using Western blot and still binds with a 
high affinity as demonstrated by SPR.  Therefore, I further investigated the functional 
relevance of this novel scFv reagent using endothelial cells as a model in vitro system, with 
cell toxicity determined by WST-8 assay. Endothelial cells (EAhy926) were treated with a 
series of calf thymus histone concentrations (10, 20, 50, 100, 200, 300 µg/mL). Histones 
were significantly toxic (200 µg/mL) to endothelial cells (EAhy926) (Fig. 2.9A), and the 
cytotoxicity of histones was dose-dependently reduced by MahscFv-Fc, which reached 
significance at 100 µg/mL (Fig. 2.9B). 
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Figure 2.9 Effect of MahscFv-Fc on histone-induced endothelial toxicity to histones. (A) 
1.5 × 10
4
 of EA.hy926 cells were cultured on a 96-well-plate and treated with a series of calf 
thymus Histones concentrations (10, 20, 50, 100, 200, 300 µg/mL), (B) or cells were treated 
with 250 µg/mL of calf thymus Histones in the presence of MahscFv-Fc (20, 50, 100, 200 
and 300 µg/mL) and incubated for 1 h. Cells were incubated with 10 µL of WST-8 for 4 h 
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and absorption read at OD450nm. Means ± SD are shown. *p < 0.05 compared with untreated 
cells and without MahscFv-Fc using ANOVA test. 
 
2.3.8 Detoxifying histones on endothelial cells in vitro with HahscFv  
I utilized the in vitro endothelial cells (EAhy926) model system, using PI and flow cytometry 
to determine the effectiveness of HahscFv against histone-toxicity. Cells were cultured with 
50 µg/mL histones, and increasing concentrations of HahscFv were used to investigate the 
protective effect of MahscFv (Fig. 2.10). The endothelial cell (EAhy926) viability was 
increased by 50 µg/mL Hahscfv (Fig. 2.10A). Further dose-dependent investigation showed 
that HahscFv reached significance at 50 µg/mL and the protective effect was even more 







Figure 2.10 Typical flow cytometry diagrams of histone cytotoxicity and HahscFv 
protection. (A) EAhy926 Endothelial-like cells were incubated in 2% FBS with or without 
50µg/mL calf thymus histones, pre-incubated without or with 50 µg/mL HahscFv for one 
hour. Cells were stained with propidium iodide (PI) (10µg/mL) prior to flow cytometric 
analysis. (B) EAhy926 cells were treated with 200 µg/mL histones with or without increasing 
concentrations of HahscFv for one hour (n=4). *p < 0.05 compared with untreated cells and 

















Extracellular histones have been found to be toxic to endothelial cells and are a major 
mediator of death in sepsis. This toxicity could be reduced using both mouse monoclonal 
antibodies and activated protein C (APC) [173]. However, APC has been withdrawn from 
clinical trials [174]. Heparin is another reagent for detoxifying histones, but as observed with 
APC, carries the increased risk of bleeding. Although non-anticoagulant heparins have been 
developed and show some protective effects [92], the other side effects, such as heparin-
induced thrombocytopenia, may prevent its application. Therefore, more effective reagents 
with fewer side effects are needed to detoxify histones. In addition, mouse anti-histone 
antibodies are also required for scientific research in mouse models. In this Chapter, I have 
developed MahcFv, MahscFv-Fc and HahscFv and tested their functions in reducing 
cytotoxicity of histones both in vitro and in vivo. These ahscFvs bind to nearly all individual 
histones but with different affinities. This may be due the nature of charges or sequence 
similarity of individual histones. These interactions are not non-specific, because they do not 
bind to S100P protein and control scFv does not interact with any of the individual histones 
(Fig. 2.4). Due to the limitation of the resources, I cannot measure the kinetics of each ahscFv 
to each individual histone. Instead, I have measured the kinetics of each ahscFv to calf 
thymus histones, a mixture of individual histones. Most of their Kds are in μM level and 
sufficient for functional analysis. 
In vitro, I have tested their protective effects on endothelial cells exposed to histones and 
found that ≥ 50 µg/mL showed a protective effect to cells treated with 50 µg/mL histones, 
using molar ratio of approximately 1:2 (ahscFv:histones). With increased ahscFv 
concentrations, the protective effects are further increased. In addition, the MahscFv is able to 
protect cultured cardiomyocytes treated with histones in vitro. In vivo, the MahscFv is not 
only able to rescue the mice challenged with lethal dose of histones but also improve the 
63 
 
cardiac performance in septic mice models (Fig. 2.8). Those data strongly indicate that the 
MahscFv is an effective reagent to detoxify histones both in vitro and in vivo. 
scFv, composed with a heavy and light linked by a flexible linker, not only retains the 
functions of intact antibody, but also had a number of advantages.  For example,  the 
relatively small size of scFv protiens make it easy to produce using recombinant DNA 
technology [140]. The disadvantage is that the most of the scFvs are not soluble when they 
are expressed in bacteria. As such, MahscFv, MahscFv-Fc and HahscFv were insoluble. 
Therefore, those proteins have to be denatured to make them soluble and refolding 
procedures were required. There may be two reasons for inclusion body formation, one is that 
expressed protein is deposited as aggregates because large amount of misfolded proteins are 
expressed. Another is that bacteria did not support post-translational modifications that are 
required to ensure correct protein folding [175].  In the future, we can utilize a mammalian 
expression system, such using Chinese hamster ovary (CHO) cells or human embryonic 
kidney 293 (HEK 293) cells to see if this can be improved.  
We found that MahscFv could reduce the toxic effects of histones but cannot reduce the 
levels of histones. This is maybe due to the lack of Fc fragment so the complexes cannot be 
recognised by macrophages Fc receptors. Therefore, I added Fc fragments to scFv and 
generated MahscFv-Fc. The MahscFv-Fc antibody firstly showed the specificity to histones 
using Western blotting (Fig. 2.4C), and protection of endothelial cells from histone 
cytotoxicity (Fig. 2.9B). However, I have not had the opportunity to test this in vivo. This will 
be completed in the near future.  
Exchanging the CDRs is one way to develop humanised scFv. I used mouse CDRs from 
MahscFv and human  IgG1 heavy [176] and kappa light chains as a frame  [177] to form a 
novel scFv, named HahscFv [141] which has been demonstrated to have similar binding 
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affinities to histones and are able to protect endothelial cells in vitro from histone toxicity. 
Further in vivo study will be carried out in the near future. 
 
2.5 Conclusion  
In conclusion, we are able to produce a functionally effective MahscFv, MahscFv-Fc and 
















Chapter 3 Isolation, Identification, Production and Characterisation of Anti-Histone 
Antibodies from SLE Patients 
 
3.1 Introduction 
Humanised antibodies still retain sequences from animals i.e. murine CDRs from mice which 
are foreign to humans. Therefore, there is still a risk of triggering host antibody production 
against the therapeutic antibody.  However, this chance is substantially lowered when using 
humanised compared to non-humanized antibodies. Therefore, a new approach is to use 
antibodies from patients with auto-immune diseases, although controversy still remains over 
the roles of auto-antibodies in human disease. Circulating autoantibodies against histones are 
present in more than 70% of SLE patients [178-183]. These anti-histone autoantibodies have 
previously been isolated and sequenced through labour intensive and costly approaches such 
as N-terminal peptide sequencing which require tailored chemical reactions, based on the 
amino acid composition [98].   
In last two decades, human antibody libraries (from B cells) have been extensively studied. 
New screening methods, such as phage display, RNA display and even DNA display libraries 
(see section 1.5) have been developed. Therefore, it is practical to obtain the coding 
sequences for an antibody fragment against a specific antigen. However, it is labour intensive 
to construct a human antibody library from patients with anti-histone antibodies with no 
guarantee that the coding sequence for anti-histone antibodies will subsequently be included 
in the library. Another disadvantage is that many studies found that the coding sequences 
isolated from human B cell libraries only code antibodies with lower affinity to antigens 
[184]. Therefore, further modification of these antibodies is unavoidable and also labour 
intensive.   
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With the wide application and technological advancement of mass spectrometry in peptide 
sequencing, it is possible to map the CDR sequences of isolated antibodies [144]. Since it is 
relatively simple to isolate anti-histone antibodies using affinity chromatography, I decided to 
explore this novel proteomic approach to obtain the specific peptide sequences of anti-histone 
antibodies from SLE patients, and then produce a human scFv against histones. An outline of 
an experimental plan for isolation and production of the human anti-histone antibody is 
shown in Fig. 3.1. 
 
 







3.2.1 Detection of anti-histone autoantibodies in serum from SLE patients  
The detection of the presence of autoantibodies to histones in the sera taken from patients 
with SLE has been previously described [185], with several modifications in this study. 
Briefly, human recombinant histones (H1.0, H2A, H2B, H3.1 and H4) (NEB, USA), mixed 
calf thymus histones (ctH) (Roche, UK) and recombinant S100P (negative control) were 
subjected to 15% SDS-PAGE in reducing conditions and transferred onto 0.45 µm PVDF. 
The membrane was blocked for 1 h at room temperature in 30 mL blocking buffer (TBST 
with 5% (w/v) skimmed milk, 2% (w/v) bovine serum albumin (BSA)). The membrane was 
then probed in blocking buffer with serum from individual SLE patients acting as primary 
antibody ((1:200 (v/v) dilutions) at 4
o
C overnight), and detected with goat anti-human IgG-
HRP (secondary antibody 1:10,000 (v/v) dilution in blocking buffer, 1 h at room 
temperature). Bands were visualized using chemiluminescence (also see chapter 2, section 
2.2.13). Normal healthy serum served as negative control. In addition, the membrane was 
directly probed with goat anti-human IgG-HRP to ensure no cross-reactivity (false positive) 
from the secondary antibody. 
 
3.2.2 Isolation of total antibodies from serum  
Antibody isolation was previously described [186] and used in this study. In brief, human 
serum was diluted by 2 × PBS and filtered with 0.45 µm filter. Human antibodies were then 
isolated using Pierce® Chromatography Cartridges Protein A/G (Thermo Fisher Scientific, 
USA) following manufacturer’s instruction. The 5 mL column was first equilibrated with 50 
mL PBS. Then the diluted and filtered serum was applied to the column. After washing with 
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100 mL PBS, the bound proteins were eluted with 20 mL of 0.1 M Glycine (pH 3.0), 
collected in small fractions (1 mL) and neutralised by adding 100 µL of 1 M Tris-HCl (pH 
8.0).  
 
3.2.3 Isolation of anti-histone antibodies from total antibodies  
Calf thymus histone-conjugated CNBr-activated Sepharose 4B media (GE Healthcare, UK) 
were used. Briefly, 1 g of the Sepharose media was activated with 100 mL of 1 mM HCl for 
1 h at 25°C, with 110 rpm rotation. The activated Sepharose was then transferred to a blank 
column and washed with 60 mL coupling buffer (0.1 M NaHCO3, 0.5 M NaCl (pH 8.3)) and 
then coupled to 5 mg calf thymus histones in the coupling buffer overnight. Then the column 
was blocked with 0.1 M Tris-HCl (pH 8.0).  The coupling efficiency was calculated as 
following:  
Total histone 5 mg – Unbound histone 0.1 mg
Total histone 5 mg
 × 100% = 98%  
 
To isolate antibodies that bind to histones, the column was first equilibrated with 20 mL 
binding buffer (20 mM Tris-HCl, 150 mM NaCl, 2 mM CaCl2, pH 7.4). The total antibodies 
isolated using Protein A/G beads from human SLE serum were then applied onto the column. 
After washing with 50 mL washing  buffer (binding buffer + 0.05% (v/v) Tween-20) 
followed by 50 mL binding buffer without detergent, the column was eluted with elution 




3.2.4 Two-dimensional (2D) gel electrophoresis 
The anti-histone antibody eluate from above was dialysed against PBS. After dialysis, the 
antibodies were precipitated using acetone (1:4) (v/v) overnight at -20°C and pelleted by 
centrifugation at 20,000 × g for 15 min. The pellet was washed with acetone twice and air 
dried on ice, and then re-suspended with 200 μL of rehydration buffer (8 M urea, 2% (w/v) 
CHAPS, 0.5% (v/v) IPG buffer, 20 mM DTT and Bromophenol blue trace). The suspended 
antibodies were uniformly loaded onto an 11 cm rehydration/equilibration tray with an 11 cm 
strip (pH 3-10 from Bio-Rad). The strip was conducted by passive rehydration at 250 V for 
12 h at 20 °C in the PROTEAN IEF cell (Bio-Rad, USA), followed by isoelectric focusing 
(IEF) of a total of 55,000 volt hour using voltage stepping: 2.5 h at 8,000 volt, and 35,000 
volt-hour at 8,000 volt. Then the strip was equilibrated with 2 mL of equilibration buffer (6 
M urea, 30% (v/v) glycerol, 2% (w/v) SDS, 50 mM Tris-Cl pH 8.8, 1% (w/v) DTT) for 10 
min at room temperature and placed on the top of a 1.5 mm thick, 16 × 18 cm SDS-gradient 
gel (7% – 18%) in a SE 600 Chroma vertical electrophoresis unit (GE healthcare, USA). 
After electrophoresis, the gel was stained using either Coomassie brilliant blue staining (see 
chapter 2, section 2.2.11) or silver staining.  
 
3.2.6 Silver staining  
After electrophoresis, the gel was silver stained [187]. In brief, the gel was firstly fixed with 
40% (v/v) ethanol, 10% (v/v) acetic acid for 60 min and washed two times with 10 % (v/v) 
ethanol, then three times with H2O for 5 min. After washing, the gel was stained using 0.2% 
(w/v) AgNO3 for 30 min and rinsed in H2O for 5 s. The gel was then developed in 2.5% (w/v) 
sodium carbonate containing 0.008% (v/v) formaldehyde until the solution turned brown. The 
reaction was terminated immediately by adding 1% (v/v) acetic acid for 5 min and then 
washed 6 times with H2O for 5 min per each step. The gel was finally reduced with 0.3% 
70 
 
(w/v) sodium thiosulphate, 0.15% (w/v) potassium ferricyanide and 0.05% (w/v) sodium 
carbonate and washed for 5 min with water five times.   
 
3.2.7 In-gel digestion for tandem mass spectrometry (MS/MS) 
In-gel digestion was performed on coomassie stained gels, as described previously [188] with 
slight modification. Gel slices were incubated in following reagents sequentially, 200 μL 
MillQ H2O, acetonitrile, 100 mM ammonium bicarbonate, 100 mM ammonium bicarbonate 
containing 50% (v/v) acetonitrile and acetonitrile, 15 min/per step. Gel pieces were then dried 
by speed-vac.   
Alternatively, if the gel was silver stained, reduction and alkylation of the proteins was 
performed. Gel slices were then incubated with 200 μL of 10 mM DTT containing 20 mM 
Ammonium Bicarbonate for 60 min at 56°C. The tube was cooled to room temperature and 
200 μL of 50 mM Iodoacetamide (IAA) was added and incubated in the dark for 30 min. The 
gel was incubated through a series of incubations with 200 μL 100 mM ammonium 
bicarbonate, 100 mM ammonium bicarbonate containing 50% (v/v) acetonitrile, 15 min/each 
step and dried using speed-vac. For the digestion, 12.5 µg/mL Trypsin, Chymotrypsin or Glu-
C, 5 µg/mL Lys-C or 2 µg/mL Asp-N at 30°C for 16 h. After digestion, an equal volume of 
acetonitrile was added into the digestion mixture and incubated for 15 min. Then the digest 
was transferred to a new tube and dried using speed-vac. The dried powder was then 
resuspended with 50 µL 1% (v/v) formic acid and 15 µL of the peptide suspension was 





3.2.8 Antibody identification using nano-flow liquid chromatography coupled to mass 
spectrometry (LC-MS/MS) 
The digested heavy and light chains of the anti-histone antibodies were identified using LC-
MS/MS at the FingerPrints Proteomics Facility, Dundee University, as previously described 
[189]. Peptide analysis was carried out on a Velos orbitrap mass spectrometer coupled with a 
Dionex Ultimate 3000 Rapid Separator. Prior to loading of 15 µL samples containing 
digested peptides onto a trap column (100 μm × 2 cm, PepMap nanoViper C18 column, 5 
μm, 100 Å, Thermo Scientific), the column was equilibrated in 98% buffer A (2% (v/v) 
acetonitrile and 0.1% (v/v) formic acid), and washed by the same buffer as above for 3 min. 
was connected after washing. Peptides were loaded on to a resolving C18 column (75 μm × 
50 cm, PepMap RSLC C18 column, 2 μm, 100 Å, Thermo Scientific) and eluted with a 
gradient concentration of 98% buffer A and 40% buffer B (80% (v/v) acetonitrile, 0.08% 
(v/v) formic acid) with a 300 nL/min flow rate for 68 min. Peptides were then analysed with 
LTQ-Orbitap Velos with the resolution set at 60,000.  
 
3.2.9 Peptide sequence analysing via PEAKS software 
The raw data was processed in PEAKS 7. Briefly, a data search against UniProtKB/Swiss-
Prot and National Center for Biotechnology Information (NCBI) nonredundant (nr) was 
performed with a precursor mass tolerance of 10.0 ppm, 0.5 Da fragment ion tolerances to 
specify each sample as raw data using various enzyme digestions. The fixed and variable 
modifications use carbamidomethylation of Cys, Oxidation of Met and Deamidation of 
Asn/Gln with a 1% false discovery rate (FDR). The peptide sequence was mapped using 
PEAKS SPIDER including posttranslational modifications (PTM). The antibody sequence 





3.2.10 Recombinant human anti-histone antibody production  
Based on the peptide sequence obtained above, the coding DNA sequence was simulated 
using the Phyre server [190]. The coding DNA for a scFv human sequence was synthesised 
by life technology containing BamHI and NdeI restriction sites. The DNA was amplified 
using polymerase chain reaction (PCR) and digested with NdeI and BamH1 restriction 
enzymes. The isolated insert was ligated with a digested pET-16b vector and sub-cloned into 
DH5α E.coli. The plasmids containing the correct coding DNA sequences were subsequently 
transformed into BL21 (DE strains), to express proteins at 18°C for 16 h. The production 
procedure was the same as described in Chapter 2, section 2.2.10.  
 
3.2.11 No.2 human anti-histone antibody antibody affinity measurement 
Surface plasmon resonance (SPR) is a commonly used method to measure the binding 
affinities [191-193]. Sensor Chip coated with streptavidin (SA) (GE Healthcare, UK) was 
used on the Biacore™ X100 (GE healthcare, UK) platform for the whole project. This is 
because that SA directly binds to histones with high affinities [171]. Briefly, calf thymus 
histones were captured on flow cell 2 of the SA chip with flow cell 1 as control and a series 
of concentrations of anti-histone antibodies were applied to the surfaces   (0.125, 0.25, 0.5, 
0.75, 1.0, 1.5, 2.0 and 3.0 µM) .  
 
3.2.12 Recombinant human anti-histone antibody functional assay  
EA.hy926 cell culture has been described in chapter 2, section 2.2.15. Briefly, confluent 
EA.hy926 cells were treated in 96 well plates with a series of anti-histone antibody 
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concentrations (0, 20, 50, 100, 200 and 300 µg/mL) for 10 min. 250 µg/mL calf thymus 
histone were added and incubated with the antibodies for 4 h. 10 µL of WST-8 dye was then 
added to 100 µL fresh media and incubated with the cells for a further 4 h.  After incubation 
the OD450nm reading was recorded.  
 
3.2.13 Antibody-mediated protection against histones in vivo 
C57BL/6 male mice were used to investigate the effect of human anti-histone antibody 
against calf thymus histone-induced toxicity; these procedures were performed according to 
state laws and operated in Southeast University in China, who holds a full animal license for 
using mice. 75 mg/kg calf thymus histones were infused through a tail vein, or 10 mg/kg of 
either heparin or No.2 human anti-histone antibody was injected 10 min prior to histones 












3.3 Results  
3.3.1 Anti-histone antibodies are present in the sera of patients with SLE 
The presence of anti-histone antibodies in SLE sera was determined using Western blotting. 
Human individual histones, calf thymus histones and S100P (negative control) were 
separated by SDS-PAGE and bands were observed after Coomassie brilliant blue staining 
(Fig. 3.2A).  Proteins on duplicated gels were transferred onto PVDF membranes which were 
probed with either control human IgG (Fig. 3.2 B), healthy sera (Fig. 3.2C) or SLE sera (Fig. 
3.2D) and detected with anti-human-HRP.  Non-specific S100P bands appeared on all 
membranes (Fig. 3.2B-D). Antibodies that bind to histones were only present in SLE serum 
(Fig. 3.2D). Sera from 4 patients with SLE (From Dr. Andy Cross, Aintree Hospital) were 
detected, but only one (Fig 3.2D) showed a strong signal for histones (Data not shown). Only 
the serum containing anti-histone antibodies was used for further analysis. 
 
Figure 3.2 Screening for autoantibodies to histones in SLE sera. (A) 2 µg of recombinant 
human histones (H1, H2A, H2B, H3 and H4), calf thymus histones (ctH) and S100P 
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(negative control) were subjected to SDS-PAGE and stained with Coomassie Blue, (B) or 
probed with IgG antibodies after transfer onto a PVDF membrane, (C) probed with healthy 
sera, (D) probed with SLE sera. 
 
3.3.2 Anti-histone antibodies were isolated from the SLE serum 
Total antibodies were firstly isolated from the SLE serum using protein A/G resin. Next, 
polyclonal antibodies of anti-histone were purified using calf thymus histone-conjugated 
sepharose resin. The isolation procedures were monitored by Western blotting as described 
above. The isolated total antibodies (Fig. 3.3A) and histone specific antibodies (Fig. 3.3B) all 
recognised the same individual histones as that of the original serum. 
 
 
Figure 3.3 Purified human anti-histone antibodies from SLE serum were examined 
against histones. (A) 2 µg recombinant human histones, calf thymus histones (ctH) and 
S100P (negative control) were subjected to SDS-PAGE and probed with total antibodies 
isolated antibodies from SLE serum, or (B) probed with purified anti-histone antibodies using 




3.3.3 Human anti-histone antibody sequences were identified   
The purified human anti-histone polyclonal antibodies were run on a two-dimensional gel in 
order to separate the Heavy and Light chains (Fig. 3.4A). The subsequent spots containing 
heavy and light chain were excised and digested with Trypsin, Chymotrypsin, Glu-C, Lys-C 
and Asp-N and analysed using MS/MS. A typical spectrum of heavy (Fig. 3.4B) and light 
chain (Fig. 3.4C) are displayed following trypsin digestion. PEAKS software was used to 
analyse the spectra, for each specific enzymes. The peptide sequences of variable fragment of 
light (Fig. 3.4D) and heavy chain (Fig. 3.3E) were acquired after PEAKS analysis, with 




Figure 3.4 Identification of human anti-histone antibody sequences (A) Following a two 
steps purification, anti-histone antibodies were separated by two-dimension gel 
electrophoresis. (B) Typical heavy and (C) light chain spectra are presented. (D) The peptide 
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sequence of variable fragment of the light and (E) heavy chain are aligned based on specific 
spectra analysed using PEAKS 7 software, with post-translation modification (PTM). Blue 
lines represent sequence identity with the germline sequence and coloured residues represent 
differences between sequences. CDRs of heavy and light chains are highlighted. PTM legend: 
a: Amidation (K) (+42.01), c: Carbamidomethylation (+57.02), d: Deamidation (NQ) (+0.98) 
f:Formylation (+27.99), g: Glycidamide adduct (+87.03), h: Hydroxylation (+15.99), m: 
Methylation (+14.02), o: Oxidation (M) (+15.99), p: Phosphorylation (STY) (+79.97), s: 
Sodium adduct (+21.98) and  : Mutation. 
 
3.3.4 Human anti-histone antibodies were successfully produced  
The complete peptide sequences of the variable regions of both heavy and light chains were 
used to design a scFv with a commonly used linker (Fig. 3.5A) and the predicted structure is 
shown in Figure 3.5B. The sequences of both the light and heavy chains of the isolated 
human anti-histone antibodies were identical. However, there are 4 possible variable regions 
for the heavy chains. Therefore, 4 antibodies were designed based on different CDR 
sequences obtained from MS/MS and named No.1, No.2, No.3, and No.4 human anti-histone 
antibody. The coding DNA sequences were optimised, synthesised and subcloned into a pET-
16b vector. The proteins were expressed in Shuffle
®
 T7 express competent E. coli. After 
purification using on-column refolding, each scFv was separated by SDS-PAGE and stained 
with Coomassie brilliant blue (Fig. 3.5C – F). For each of the anti-histone antibodies, the 





Figure 3.5 Recombinant human anti-histone antibody productions. (A) Antibody design 
template, including variable light and heavy chains with a flexible linker, and linked with 
CH1, CH2 and CH3 domains. (B) Template peptide sequence of a recombinant human anti-
histone antibody was designed as illustrated. Four antibodies (B) Antibody No.1, (C) No.2, 
(D) No.3 and (E) No.4 were produced with integrated CDRs, specifically targeted against 
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histones. Four sequential column elution steps (Elution No. 1-4) for each antibody were 
separated by 12% SDS-PAGE and visualised by Coomassie brilliant blue staining.  
 
3.3.5 Human anti-histone antibodies bind to histones with high affinity 
To explore the specificity and affinity of the recombinant human anti-histone antibodies to 
histones, human histones and control proteins were subjected to Western blotting, and these 
antibodies were used as primary antibodies. I found that all 4 of the recombinant human anti-
histone antibodies specifically bind to H1, H2B and H3 but not H2A (Fig. 3.5A – D). In 
contrast, a H4 band could only be clearly observed on the blot probed with No.2 human anti-
histone antibody, with relatively weak bands in blots probed with the other three. The affinity 
of No.2 human anti-histone antibody to histones under native condition was investigated 
using SPR. Calf thymus histones were captured on sensor chip SA and various concentrations 
of human anti-histone antibodies were used in the kinetic assays. The average Kd of No.2 
human anti-histone antibody was approximately 5.717 × 10
-7
 M (Fig 3.5E), whereas the 
affinity of No.4 antibody to histones was 3.197 × 10
-6
 M. Moreover, the Kds for No.1 and 







Figure 3.6 Human anti-histone antibody binding. (A) 2 μg of recombinant histones, mixed 
calf thymus histones and S100P (negative control) were subjected to 15% SDS-PAGE and 
probed with antibody (A) No.1, (B) No.2, (C) No.3 and (D) No.4 followed by transfer on to a 
PVDF membrane. (E) Calf thymus histones were captured on sensor chip SA, and a series of 
concentrations (0.1, 0.3, 0.5, 0.8, 1.0, 1.5, 2.0 and 3.0 µM) of No.2 antibody were used. The 
affinity between No.2 antibody and mixed histones is 5.717 × 10
-7
 M after the Biacore™ 
X100 measurement. (F) Using the same procedure as above for No.4 antibody, the affinity to 
calf thymus histones was determined to be 3.197 × 10
-6
 M.  
 
3.3.6 Human anti-histone antibodies protect endothelial cells from histone toxicity 
The cytotoxicity of histones to endothelial-like cells (EAhy926) has been shown in chapter 2, 
as well as in recent publications [91, 173]. I first determined that 250 µg/mL histones were 
cytotoxic to endothelial-like cells (EAhy926) using a WST-8 assay. Next, the protective 
effect of each human anti-histone antibody against histone-induced toxicity was investigated. 
Endothelial cells were significantly protected by all antibodies (Fig. 3.6A & B) with No.2 
antibody showing a significant protective effect at concentrations as low as 50 µg/mL, 








Figure 3.7 Human anti-histone antibody protections in vitro against histone-induced 
cytoxicity. (A) In order to determine the protective effects, EA.hy926 cells were treated with 
calf thymus histones (250 μg/mL) in the absence of presence of different concentrations (20, 
50, 100, 200 and 300 µg/mL) of the No.1 and No.2 recombinant antibodies. Cell survival (%) 
was determined by WST-8 toxicity assay. (B) The same method was used to show the 
protection to histones for No.3 and No.4 antibodies. Means ±SD are shown. *p < 0.05 
compared with histones treated cells in the absence of antibodies using ANOVA test. 
  
3.3.7 Human anti-histone antibodies rescue mice infused with histones 
To further explore the protective effects of the No.2 antibody, calf thymus histones (75 
mg/kg) were infused in to mice. At this lethal dose of histones all mice died within 4 h. 
However, pre-infusion of either 10 mg/kg No.2 antibody or heparin, 10 min prior to histone-
infusion, significantly protected all mice from a lethal dose of histones (Fig 3.6C). These data 
demonstrate that No.2 antibody has an affinity to histones, and also inhibits histones-induced 
toxicity in mice.  Taken together, No.2 human anti-histone antibody binds histones, inhibits 









Figure 3.8 Effect of human anti-histone antibody against histone-induced toxicity in 
mice. Group 1; 75 mg/kg calf thymus histones were infused into 5 individual healthy mice, 
all mice died within 4 h. Group 2; 10 mg/kg No.2 antibody and 75 mg/kg histones (Hist) 
were infused into 5 healthy mice, these mice survived over 72 h. Group 3; 10 mg/kg heparin 










3.4 Discussion  
A novel approach for producing human antibodies to specific antigens has been established in 
this study.  This approach includes a two-step purification of human antibodies from sera, 2D 
gel electrophoresis, LC-MS/MS and PEAKS analysis, scFv coding sequence design and 
synthesis, recombinant antibody production and characterisation as outlined in Fig 3.1. To 
date, this approach has not been widely used, but the successful application in this study may 
encourage other groups to adopt this methodology.  This may be of particular use when a 
neutralising antibody is urgently needed to treat a new outbreak of infectious diseases. 
Normally, neutralising antibodies exist in survivors of a viral or bacterial infection. Since this 
methodological approach is rapid and robust, identification and production of a novel 
therapeutic antibody may help to stop an outbreak of previously unknown infection. In 
addition, many auto-antibodies in human sera may be identified and produced in this way for 
both research and therapeutic benefit. 
The human anti-histone antibodies isolated in this study recognise a spectrum of histones. 
This may be due to all histones having a strong positive charge or the presence of multiple 
lysine or arginine sequences. However further experiments are needed to clarify the reason 
behind this observation.  Autoantibodies to H1, H2B and H3 in SLE sera also have been 
reported previously [194, 195]. Overall, due to the broad range of histones that these 
antibodies recognise, they may in fact be more effective in detoxifying histones than an 







A proteomics approach for identification of human antibody sequence has been established. 
The recombinant human anti-histone antibodies are specific to histones and have high 
affinities. More importantly, those antibodies can reduce histone-induced toxicity to 
endothelial cells, and protect mice infused with lethal dose of histones.  Therefore, there is a 
















Chapter 4 Identification of Histone-Binding Proteins in Human Serum Using Mass 
Spectrometry 
 
4.1 Introduction  
The toxic effects of histones include coagulation activation [38], platelet aggregation [39], 
pro-inflammatory cytokine release [40, 41] and endothelial damage [173]. Moreover, 
extracellular histones and DNA are released from neutrophils to form NETs, which facilitate 
thrombus formation and are relevant in models of deep vein thrombosis, transfusion-related 
acute lung injury, cancer, trauma and sepsis [14, 36, 42-44].  
Histones-triggered harmful effects can be reduced by protein APC, an enzyme that cleaves 
histones, antibodies that neutralise histones [14], CRP [91], albumin [196] and heparin [92] 
that bind to histones. It is also reported that many plasma proteins could be co-precipitated 
with histones [93]. Moreover, we found that 20 µg/mL histones are significantly cytotoxic to 
endothelial cells in the absence of serum or plasma  [91]. In contrast, >50 µg/mL histones in 
plasma show toxic effects on these cells [48]. However, the major proteins that strongly 
interact with histones in plasma are not fully clarified. In this study, I will isolate histone-
binding proteins using a pull-down assay with high stringency and identify these proteins 









4.2.1 Isolation of histone-binding proteins from sera 
Blank and histone-conjugated Sepharose columns were prepared as described in Chapter 3, 
section 3.2.3. Normal or acute phase sera from healthy and critically ill donors were diluted 
with 2 × PBS and centrifuged at 17,000 × g for 10 min at 4°C to remove the insoluble 
contents. The harvested supernatant was then applied to the blank Sepharose column in order 
to eliminate proteins that would non-specifically bind to Sepharose. For the sera from 
critically ill patients that contain high levels of CRP, a major acute phase protein that binds to 
and detoxifies histones [91], the pass through from blank Sepharose column were further 
applied to p-Aminophenyl Phosphoryl Choline-conjugated Agarose beads (Thermo Fisher 
Scientific, USA) to avoid the interference from CRP in the subsequent steps. The CRP-free 
sera were then applied to a histone-conjugated Sepharose column. After two washes (200 mL 
of PBS containing 0.5% (v/v) Tween 20 followed by 100 mL of PBS only), histone-binding 
proteins were finally eluted with 20 mL of 100 mM Glycine, pH 3.0 and immediately 
neutralised with 2 mL of 1 M Tris-HCl, pH8.0. The eluates were separated by SDS-PAGE or 
2D gel electrophoresis which were then stained with Coomassie brilliant blue.  
 
4.2.2 Spot in-gel digestion by trypsin 
After 2-D gel electrophoresis, each spot was individually excised and digested using trypsin. 
The digested samples were then examined on LC-MS/MS, which is fully described in 




4.2.3 Histone-binding protein analysis   
The raw MS/MS data was analysed by PEAKS software using the same setting as described 
in Chapter 3 section 3.2.9.  
 
4.2.4 Western blotting 
The proteins that were identified using MS/MS mass spectrometry were further validated 
using Western blotting.  The eluates together with human antithrombin and prothrombin (as 
positive controls) were subjected to Western blotting and probed with anti-prothrombin and 
anti-antithrombin antibodies. The detailed procedures were described in details in Chapter 2 














4.3.1 CRP has been completely removed from acute phase patient sera   
CRP levels are normally less than 10 mg/L in serum, but may increase up to 1,000 fold in 
severe disease conditions [197]. CRP interacts with histones [91]. Therefore, high levels of 
CRP may interfere with the isolation of other histone-binding proteins [91]. As such, the CRP 
in the serum from patients was removed by phosphocholine-conjugated beads.  Figure 4.1A 
shows that the CRP was retained in the column and can be eluted using free phosphocholine. 
However, when the pass through was applied to second phosphocholine-conjugated column, 
the CRP band was not present (Fig. 4.1A right), suggesting that CRP was completely 
removed from the serum. In addition, CRP was not identified after PEAKS analysis (Table 
4.1). The CRP-free pass through from second column was used for isolation of histone-
binding proteins.  
 
4.3.2 Histone-binding proteins can be pulled down using histone-conjugated Sepharose 
The sera proteins isolated using histone-conjugated beads were separated by 2-D gel 
electrophoresis. Following Coomassie brilliant blue staining, 7 identifiable spots were 
observed in patient (Fig. 4.1B) and normal sera (Fig. 4.1C). Taken together, histone binding 
proteins were eluted from both acute phase and normal sera and showed a similar pattern 







Figure 4.1 Histone binding protein isolation from both critically ill patient and normal 
sera. (A) CRP was twice isolated from critically ill patient sera during the acute phase of 
disease using phosphoryl Choline-conjugated beads, and then the first and second eluates 
were subjected to 15% SDS-PAGE. (B) Following CRP elimination, histone binding proteins 
were captured using affinity chromatography with a histone conjugated sepharose column 
from sera. The column eluate was separated by 2-D gradient gel (8 – 18%) electrophoresis, 
and stained with coomassie brilliant blue. Each spot (red circle) was digested by trypsin, and 
investigated using LC-MS/MS. (C) Histone binding proteins were also eluted from normal 
sera separated by 2-D gradient gel (8 – 18%) electrophoresis, and stained with coomassie 
brilliant blue. 
 
4.3.3 Identification of the isolated histone-binding proteins using mass spectrometry  
Following 2-D gel electrophoresis, each spot was excised and digested by trypsin, and 
subsequently analysed by LC-MS/MS.  The raw data was processed using PEAKS software 
and the IDs of each of the 7 spot are listed in Table 4.1. A strong spot in Figure 4.1C (red 
circle No.5), suggesting both high abundance within the serum and high affinity for histones, 
was identified using mass spectrometry, and with the raw spectrum data is displayed in figure 
4.2A. Upon analysis using PEAKS software, human antithrombin (protein identification in 
UniProt is P01008 and molecular weight is 52.6 kDa) was identified and confirmed by 
sequence alignment (Fig. 4.2B), which showed a peptide coverage of 74% when compared to 
the template sequence. Spot No. 7 in figure 4.1C was also identified by MS/MS and the raw 
data is displayed in figure 4.2C.  Following PEAKS analysis, human prothrombin (protein 
identification in UniProt is P00734 and molecular weight is 70 kDa) was identified and 
confirmed by sequence alignment (Fig. 4.2D), with 40% peptide coverage compared to the 



















P62805 H4 Human Histone H4 
 
51 6 11.4 12 1 
P58876 H2B1D Human histone H2B 
 
38 6 13.9 12 1 
P62805 H4 Human Histone H4 
 
51 6 11.4 13 2 
P58876 H2B Human histone H2B 
 
46 6 13.9 13 2 
Q99879 H2B1M Human histone H2B 
 
30 4 14.0 14 3 
P16104 H2AX Human Histone 
H2A 
 
24 3 15.1 14 3 
P10909 CLUS HUMAN Clusterin 
 
77 88 52.5 32 4 
P01008 ANT3 HUMAN 
Antithrombin-III 
74 59 52.6 47 5 
P00734 THRB HUMAN 
Prothrombin 
37 57 70.0 47 5 
P04004 VTNC HUMAN 
Vitronectin 
75 75 54.3 47 5 
P04004 VTNC HUMAN 
Vitronectin 
69 86 54.3 65 6 
95 
 
P01876 IGHA1 HUMAN Ig alpha-1 
chain C region 
67 32 37.7 65 6 
P01877 IGHA2 HUMAN Ig alpha-2 
chain C region 
44 23 36.5 65 6 
P01019 ANGT HUMAN 
Angiotensinogen 
39 13 53.2 65 6 
P00734 THRB HUMAN 
Prothrombin 










Figure 4.2 Human antithrombin and prothrombin identification using MS/MS and 
PEAKS. (A) A spectrum raw data of spot No. 5 was defined and the spectrum is displayed. 
(B) The raw data was analysed by PEAKS, and human antithrombin was identified with 74% 
peptide coverage using the NCBInr database. (C) A mass spectrum was acquired from spot 
No.7. (D) After PEAKS analysis, prothrombin could be identified (with 40% peptide 
coverage).  
 
4.3.4 Western blotting verifies these identified histone-binding proteins 
To further confirm that the isolated histone-binding protein eluate contains antithrombin and 
prothrombin, the histone binding-protein elution was subjected to Western blotting and 
probed with either anti-antithrombin (Fig. 4.3A) or anti-prothrombin (Fig. 4.3A) antibodies, 





Figure 4.3 Confirmation that human antithrombin and prothrombin are histone-
binding proteins present in serum. (A) The eluate from histone-conjugated sepharose beads 
was separated by SDS-PAGE and probed with an ant-antithrombin antibody (left panel), with 
purified human anit-thrombin as a positive control (right panel). (B) Western blotting was 
performed on the eluate with an anti-prothrombin antibody (left panel), with purified 






4.4 Discussion  
In this study, I used a highly stringent approach to isolate histone-binding proteins in sera. 
This is different from previous publications [93]. With the high stringency, only the proteins 
that tightly bind to histones are isolated or those pursent at high concentrations. Therefore, 
previously reported histone-binding proteins such as albumin and complement components 
[93], were not pulled down. Histones were also bound and isolated using this method due to 
their high binding affinities within the nucleosome.  If histones are present in the serum it 
would therefore be expected that histone H3, when conjugated on the Sepharose beads, could 
pull-down H4 and vice versa.  Similarly, H2A would be able to bind to H2B and thus be 
present in my data analysis.  Since this is a well-known fact, I did not pursue this 
investigation further.  
The most interesting finding is that antithrombin and prothrombin were pulled down using 
this highly stringent method. Although these proteins have previously been shown to interact 
with histones, this is the first report that they can be directly pulled down from human serum. 
This finding also provides further evidence as to why high levels of circulating histones cause 
significant coagulation abnormalities [48]. By confirming these data using Western blot, I am 
confident that these findings are robust.  Therefore, in the next Chapter I will investigate the 
functional role of the interaction between histones and prothrombin. 
 
4.5 Conclusion 
Histone-binding proteins have been identified using mass spectrometry and analysed using 
PEAKS software. Human antithrombin and prothrombin bind to histones, which had been 
confirmed by Western blot. Further characterization of the binding between histones and 
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prothrombin, as well as the role of this binding in enhanced prothrombin activation will be 




Chapter 5 Extracellular Histone Enhanced Prothrombin Activation is Reduced by Anti-
Histone Treatment 
 
5.1 Introduction  
Extracellular histones have been characterised in the promotion of coagulation and 
thrombosis. The pro-coagulant properties of histones include endothelial damage with release 
of vWF, platelet activation and thrombin generation from loss of thrombomodulin (TM)-
dependent protein C anticoagulant effects [14, 45, 46]. In vivo histone infusion in mice results 
in rapid thrombocytopenia and platelet consumption in thrombi.  Further evidence to support 
the role of histones in the activation of coagulation has been demonstrated by our group. In 
mouse models, plasma TAT complexes were significantly elevated following either trauma 
(endogenous histone model) or histone infusion (exogenous histone model) [48]. 
Pathologically, the lungs were the predominantly affected organ with neutrophil infiltration, 
pulmonary edema, haemorrhage, and microvascular thrombosis. The formation of thrombi in 
lungs strongly supports the hypothesis that histone-triggered coagulation activation is 
involved in lung injury and possibly MOF. 
Thrombin is a pivotal molecule in the coagulation cascade. The regulation of thrombin 
generation is critical to  the balance of bleeding and vascular occlusion [198]. Prothrombin is 
a zymogen form and its assembly factor (F) Xa, co-factor FVa in the presence of calcium 
ions and phospholipids constitutes the prothrombinase complex that facilitates thrombin 
generation. The relationship between prothrombin levels and thrombin generation is 
strikingly different from other coagulation factor. The rate of thrombin generation, peak 
activity reached and free total amount of thrombin produced are proportional to free thrombin 
levels [199].  
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Prothrombin or coagulation factor II, is a single chain protein composed of fragment 1 (F1) 
(residues 1 – 155), F2 (residues 156 – 271) and protease domain (α-thrombin) (residues 272 – 
579). There are two cleavage pathways in the prothrombinase complex [25]. Prothrombin is 
initially cleaved at Arg-271 to split into two parts; Fragment 1.2 complex, and prethrombin-2. 
Moreover, prothrombin is cleaved at Arg-320 to form meizothrombin, because A and B chain 
are connected by a disulphide bond (Cys-293 and Cys-439). In addition, prothrombin can be 
activated via cleaving residue Arg-271 on the platelet surface under physiological conditions 
[25].  
Histone H4 has been recently found to promote prothrombin autoactivation [20].  In this 
study fluorescent titrations were used to demonstrate that H4 directly binds to prothrombin. 
Furthermore, they demonstrate that this has functional relevance through H4-induced 
prothrombin cleavage. However, since this reaction took up to 8 hours to occur, its 
physiological relevance needs to be further explored. In Chapter 4, I have directly pulled 
down prothrombin using histone-conjugated beads from serum under highly stringent 
conditions, indicating a strong integration between histones and prothrombin. However, the 
interaction between histones and prothrombin and its functional roles have not been fully 
characterised and moreover, the role of prothrombin cofactors had not been taken into 
account. In this study, I will investigate the effect of histones on prothrombin cleavage to 






5.2.1 Recombinant HPT fragment 1 and 2 production  
Recombinant human prothrombin fragment 1 and 2 were produced in BL21 E. coli and 
purified using affinity chromatography, which has been fully described in Chapter 2, section 
2.2.9 & 10.  
 
5.2.2 Mapping the binding sites using gel overlay  
Prothrombin, prothrombin fragment 1, prothrombin fragment 2 and human α-thrombin were 
subjected to 12% SDS-PAGE and transferred to a 0.45 µm PVDF membrane. After transfer, 
the membrane was incubated with 5 µg of H3 suspended in gel overlay buffer (100 mM 
NaCl, 50 mM Tris-HCl, 2 mM CaCl2, 2 mM DTT, 0.5% (w/v) BSA, 0.25% (w/v) gelatin 
(Sigma, USA) and 0.5% (v/v) IGEPAL
®
 CA-630 (Sigma, USA)) overnight at 4°C. The 
membrane was then washed the following day with overlay washing buffer (100 mM NaCl, 
50 mM Tris-HCl, 2 mM DTT, and 0.5% (v/v) IGEPAL
®
 CA-630) twice and TBS-T three 
times, which was continually blocked with blocking reagent (TBST, 2% (w/v) BSA and 5% 
(w/v) milk) for two hours. Primary (anti-H3 antibody) and secondary (anti-IgG-HRP 
antibody) were used as per western blot protocol which was described in Chapter 2, section 
2.2.13.  
 
5.2.3 Predicted interaction between Prothrombin and H4 using the ZDOCK server  
Prediction of the interaction between prothrombin and H4 was performed by docking, using 
ZDOCK server as described in reference [200]. Briefly, the ZDOCK server website 
(http://zdock.umassmed.edu/) was used to simulate the protein-protein interaction. The input 
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receptor was prothrombin (4NZQ in protein data bank (PDB)) and the input ligand was H4.1 
(Q757K0 in PDB). The job ID is 80836.  
 
5.2.4 Determination of binding affinity and the effects of anti-histone reagents  
The SPR system with Sensor Chip SA has been described in chapter 3 to measure the 
antibody-antigen affinity. In this chapter, histones were captured on Sensor Chip SA to 
investigate the affinity between histone and prothrombin. 
Biosensor system including Sensor Chip SA was primed with suspending buffer (100 NaCl, 
20 mM Tris-HCl, pH 7.4). 20 µg/mL of each recombinant histone H1, H2A, H2B, H3 and H4 
was captured on flow cell 2 (Fc2) with Fc1 set as blank. Increasing concentrations of 
prothrombin (0.125, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0 and 3.0 µM) were loaded on sensor Chip SA 
through Fc1 (blank) and Fc2 (histone) with a regeneration step (20 mM HCl) between each 
histone concentration. Kd values were calculated using the binding to Fc2 (histone) – Fc 
(blank).  
When testing the effect of blocking H4 binding to prothrombin using either ahscFv or 
heparin, H4 was first coated on to Fc2. 1.5 µM of heparin, control scFv and MahscFv were 
individually added to Fc 2, with Fc1 as a blank. 1.5 µM of prothrombin was then applied on 
both Fc2 and Fc1. Response unit was calculated by Fc2 – Fc1. 
 
5.2.5 Prothrombin cleavage 
Prothrombin cleavage assay was performed, as described previously [25]. Briefly, 
prothrombin was dialysed in cleavage buffer (20 mM HEPES, 150 mM NaCl, 5 mM CaCl2, 
0.1% (v/v) PEG-8000, pH7.4) for 24 h at 4°C. The cleavage assay was performed in cleavage 
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buffer, containing 1.5 µM hPT, +/-5 nM FXa and +/- 50 µg/mL H1, H2A, H2B, H3 or H4.  
When inhibitors were used heparin (6 µM) (Sigma Aldrich, UK) or ahscFv (100 µg/mL) 
were pre-incubated with histones for 10 min. All reactions were initiated upon the addition of 
prothrombin and terminated by the addition of 4 × Laemmli buffer and heated at 95°C for 10 
min. Proteins were then subjected to SDS-PAGE and visualised using Coomassie blue 
staining.  
 
5.2.6 Density quantification 
To determine the effect of each treatment on prothrombin cleavage, densitometry was 
performed. Images of coomassie-stained SDS-PAGE gels were captured on a G:BOX 
(Syngene) using GeneSnap software (Syngene) and further analysed using GeneTools 
software (Syngene). Densitometry was performed for each prothrombin band in triplicate 
using equal sized boxes for each treatment. Background was subtracted from the region 
surrounding each band to account for intra-assay variations in staining, whereas inter-assay 
variability was corrected by taking a background reading in a blank region of each gel. The 
corrected density of the untreated prothrombin was assigned the value of 100 percent and the 
density of each treatment on that gel was expressed as a percentage thereafter.   
 
5.2.7 Thrombin generation assay 
Thrombin generation measurements were performed in a 96-well plate fluorimeter 
(SpectraMax Gemini) equipped with a 360/460 nm filter set, using a fluorogenic thrombin 
substrate (Technoclone, Austria), Z-Gly-Gly-Arg-AMC. The assay was performed in 
prothrombin cleavage  buffer (total volume=100 µL), containing 1.5 µM prothrombin, +/-0.5 
nM Factor Xa and +/- 50 µg/mL H1, H2A, H2B, H3 or H4.  When inhibitors were used, 
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heparin (6 µM) (Sigma Aldrich, UK) or ahscFv (100 µg/mL) were pre-incubated with 
histones for 10 min. The reaction was initiated upon the addition of prothrombin and the 
fluorogenic thrombin substrate (50 µL) and fluorescent emissions measured at 37°C every 
min for 120 min. Sample analysis was performed using Microsoft Excel and thrombin 
concentrations (nM) were calculated using a thrombin calibration curve (10, 3 and 1 nM 
thrombin). 
For Factor X and Factor V deficient plasma, 32 µL of plasma (Haematologic Technologies 
Inc) was mixed with 50 µg/mL H4, to a total volume 40 µL. The reaction was then initiated 
by the addition of 10 µL TGA reagent C (RC) Low (containing tissue factor and 
phospholipids) (Technoclone, Austria) and 50µL Z-Gly-Gly-Arg-AMC fluorogenic substrate. 
Fluorescent measurements were taken at 1 min intervals for 60 min at 37°C. Sample analysis 
was conducted on Technothrombin TGA evaluation software (Technoclone, Austria) using a 
thrombin calibration curve and data are expressed as thrombin (nM) generation per min. 
 
5.3 Results 
5.3.1 Histones H3 and H4 bind to prothrombin 
To clarify which histones interact with prothrombin, Biacore X100 SPR system was used. 
Histones H4 and H3 showed much higher binding responses to prothrombin than equimolar 
concentration of H1, H2A or H2B. The binding affinities with H3, was Kd = 6.8 x 10
-7
 M and 
Kd = 7.0 x 10
-7 
M for H4 (Figure 5.1A). However, the Kd values for H1, H2A and H2B were 
unable to be calculated due to their very low responses. To determine which regions of 
prothrombin were the histone binding sites, the potential interaction models was first 
simulated using published 3D structures and they predicted that histones H3 and H4 may 
interact with fragments 1 and 2 of prothrombin (Figure 5.1B). To confirm this, human 
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recombinant prothrombin fragment 1 and 2 proteins were produced and a gel overlay assay 
was used to confirmed that that H3 bound to both fragments 1 and 2 of prothrombin but not 
to thrombin (B-chain) (Figure 5.1C). However, H4 bound to both fragment 1 and 2 as well as 
to thrombin, which showed slightly different binding to that of H3.  
 
 
Figure 5.1 The binding of histones to prothrombin. (A) 20 µg/mL of recombinant histone 
H1, H2A, H2B, H3 or H4 was captured on flow cell 2 and flow cell 1 set as control. Various 
concentrations (0.125, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0 and 3.0 µM) of prothrombin was then 
added to both Fc1 and Fc2. (B) Docking prediction using ZDOCK server (Job ID: 80836), 
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predicted that H4 binds to prothrombin.  Specifically, H4 recognised prothrombin fragment 1 
(peptide sequence: STATDVFWAKYTACETARTPRDKLAACLEG) and fragment 2 
(peptide sequence: WASAQAKALSKHQDFNS). (C) Equimolar concentrations of 
prothrombin (ProT), prothrombin fragment 1 (F1), prothrombin fragment 2 (F2), α-thrombin, 
antithrombin and S100P were subjected to a 12% SDS-PAGE, stained with Coomassie 
brilliant blue (right panel), and transferred to PVDF membrane and overlaid with H3 (left 
panel) or H4 (middle panel). 
 
5.3.2 Histones H3 and H4 facilitate the cleavage of prothrombin by factor Xa 
H4 has previously been shown to induce prothrombin autoactivation, which takes up to 8 
hours to occur, with H3 taking three times longer than H4 [20]. It is known that Factor Va 
interacts with both fragment 1 and 2 of prothrombin within the coagulation cascade acting as 
a co-factor to facilitate prothrombin cleavage by Factor Xa, generating active thrombin 
rapidly [201]. Given the binding data above, histones H3 and H4 may therefore behave 
similarly to that of Factor Va in promoting prothrombin cleavage by Factor Xa. Using a 
prothrombin cleavage assay, prothrombin was not cleaved in the absence of Factor Xa within 
1 h (Figure 5.2A) but enhanced cleavage occurred  from 1 min when prothrombin was co-
incubated with Factor Xa (Figure 5.2A) and either histone H4 or H3 (Figure 5.2B). Without 
histones, little prothrombin was cleaved by Factor Xa because in the absence of co-factor, 
Factor Va was missing (Figure 5.2C). Histone H4 was much more effective than H3 in 
enhancing prothrombin cleavage by Factor Xa (Figure 5.2D). In contrast, the other histones 
did not show a significant effect (Figure 5.3A). H3 and H4 significantly enhanced the 






Figure 5.2 Effect of histones H3 and H4 on prothrombin cleavage in the presence of 
FXa. (A) Prothrombin (1.5 µg/mL) was incubated without (left panel) or with factor Xa 
(FXa) (5nM) (right panel) at 37°C. Aliquots were removed at various times, as indicated, and 
subject to 15% SDS-PAGE.  The gels were stained in Coomassie blue for 1 h and destained 
overnight. (B) Prothrombin (1.5 µg/mL) was incubated at 37°C for indicated time points in 
the presence of either H3 (left panel) or H4 (50 µg/mL) (right panel), subject to SDS-PAGE 
and visualized using coomassie blue. (C) Prothrombin (1.5 µg/mL) was incubated with FXa 
(5nM) with either H3 (50 µg/mL) (left panel) or H4 (50 µg/mL) (right panel) for indicated 
time points and visualized using coomassie blue. (D) Prothrombin bands from A-C were 
quantified by densitometry and expressed as a percentage compared to T=0. The mean values 





Figure 5.3 Effect of individual histones on prothrombin cleavage. (A) Prothrombin (1.5 
µg/mL) was incubated with histone H1, H2A, H2B, H3 or H4 (50 µg/mL) without (left 
panel) or with factor Xa (FXa) (5nM) (right panel) for 1 h at 37°C, subject to 15% SDS-
PAGE and visualized using Coomassie blue. (B) Prothrombin bands from gels in (A) were 
quantified using densitometry and represent as mean +/- 1 S.D for 3 independent 
experiments. *ANOVA test shows significant increase in prothrombin cleavage compared 





5.3.3 Histone H4 more effectively enhances thrombin generation  
To generate active thrombin, Factor Xa needs to cleave 3 sites of prothrombin to generate 
fragments that include Prethrombin 1, Prethrombin 2 and the B-chain of thrombin. Mature 
thrombin contains two fragments linked by a disulfide bound (Fig. 1.2).  Under reducing gel 
conditions, a 34 kDa band, i.e. the size of the B chain would represent active thrombin. 
Interestingly, this band was clearly visualised by Coomassie brilliant blue staining only in the 
lane where prothrombin was incubated with both FXa and histone H4, but not as evident with 
H3 (Fig. 5.3). To investigate whether the enhanced FXa cleavage of prothrombin generates 
active thrombin, a fluorogenic thrombin substrate, Z-Gly-Gly-Arg-AMC, was used to 
monitor the enzyme activity of thrombin. The substrate was cleaved in the presence of H4 but 
not H3 (Fig. 5.4A).  In fact, H4 in the presence of FXa was the only histone able to result in 
the generation of active thrombin (Fig. 5.4B).   
 
 
Figure 5.4 Effect of individual histones on thrombin generation. (A) Thrombin generation 
was performed in prothrombin cleavage buffer (20 mM HEPES, 150 mM NaCl, 5 mM 
CaCl2) containing Prothrombin (1.5 µM), +/- FXa (0.5 nM) and +/- Histone (H)1, HA, H2B, 
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H3 or H4 (50 µg/mL).  The reaction was initiated upon the addition of prothrombin and the 
fluorogenic thrombin substrate, Z-Gly-Gly-Arg-AMC.  Fluorescent emissions (Ex 360/Em 
460nm) were measured at 37°C every minute for 120 minutes.  Data are representative 
fluorescent units (FU) curves generated for 3 independent experiments. (B) Graphical 
representation (Mean +/-1 S.D) of thrombin generation in (A) using a thrombin calibration 
curve to determine the concentration of thrombin (nM) generated for each treatment. 
*ANOVA test shows significant increase in generation compared with Prothrombin + FXa 
alone (P<0.05). 
 
5.3.4 Anti-histone antibodies and heparin block histone H4-enhanced prothrombin 
cleavage and thrombin generation 
To demonstrate the specificity of histone H4-enhanced prothrombin cleavage and thrombin 
generation, I used HahscFv and heparin that have been demonstrated to detoxify histones 
both in vitro and in vivo.  Both HahscFv and heparin abolished the binding of H4 to 
prothrombin in the SPR assay (Fig. 5.5A & B) and inhibited H4-enhancement of prothrombin 
cleavage (Figure 5.5C & D) and consequent thrombin generation (Figure 5.5E & F). These 
data demonstrate that the effect on prothrombin cleavage and thrombin generation appears 








Figure 5.5 The effect of anti-histone reagents against histone H4 binding to 
prothrombin, prothrombin cleavage and thombin generation. (A and B) H4 was captured 
on sensor chip SA and either incubated with 1.5 of µM HahscFv, control scFv (A) or heparin 
(B), then prothrombin (1.5 µM) added to the flow cell and binding curves were obtained for 
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60 seconds. Curves are representative of 3 independent experiments. (C and D) Prothrombin 
(1.5 µg/mL) was incubated with FXa (5 nM) and H4 (0, 10, 20 or 50 µg/mL), (C) with or 
without HahscFv (100 µg/mL) or (D) Heparin (6 µM)  at 37°C for 60 min. Samples were 
subject to 15% SDS-PAGE and gels stained with Coomassie blue.  Prothrombin bands were 
then quantified by densitometry and expressed as a percentage of undigested prothrombin on 
the same gel. The mean +/- 1 S.D for >3 independent experiments are shown. (E and F) 
Prothrombin (1.5 µg/mL) was incubated with factor Xa (FXa) (0.5nM) with H 4 (0, 10, 20 or 
50µ/mL), (E) with or without ahscFv (100 µg/mL) or (F) Heparin (6 µM). Upon initiation of 
the reaction changes in fluorescence were monitored at 37°C every minute for 120 minutes. 
Mean +/- 1 S.D of thrombin generated at the end of the reaction is shown. *ANOVA test 
shows significant increase compared with Prothrombin + FXa alone (P<0.05).  
#
ANOVA test 
shows significant reduction in the presence of ahscFv or heparin compared to that without 












5.3.5 Histone H4 replaces FVa to stimulate thrombin generation in FV deficient plasma 
but not for  FX deficiency 
Since histone H4 interacts with both fragment 1 and 2 of prothrombin to enhance 
prothrombin cleavage and thrombin generation by FXa in a similar manner to FVa, I used FV 
deficient plasma to investigate whether histone H4 could replace FVa within the coagulation 
cascade. The addition of 50 μg/mL histone H4 to FV deficient plasma restored thrombin 
generation (Fig. 5.6A). In contrast, histone H4 did not restore the cascade when added to FX 
deficient plasma (Fig. 5.6A). However, adding H4 to FX deficient plasma supplemented with 
FXa enhanced thrombin generation, indicating histone H4 has an additive effect in the 
presence of FV (Fig. 5.6B). 
 
 
Figure 5.6 Effect of histone H4 in the generation of thrombin in FV and FX deficient 
plasmas. (A) Thrombin generation in FV and FX deficient plasma was performed with or 
without H4 (50 µg/mL). (B)  Thrombin generation was performed in FX deficient plasma in 
the presence or absence of FXa (0.5 nM) +/- H4 (50 µg/mL). The reactions were initiated by 
the addition of TGA reagent C (RC) Low (containing tissue factor and phospholipids) and 
fluorescence generated by the cleavage of the fluorogenic thrombin substrate, Z-Gly-Gly-
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Arg-AMC. Measurements were taken at 1 min intervals for 60 min at 37°C.  Representative 





















This work demonstrates that extracellular histones can enhance prothrombin activation.  
Specifically, histone H4 increases Factor Xa-induced prothrombin cleavage, which results in 
thrombin activation.  In this way, H4 could replace Factor Va in the coagulation cascade and 
facilitate thrombin generation.  
Previously, pro-coagulant properties of histones have partly been attributed to the loss of 
thrombomodulin (TM)-dependent protein C anticoagulant effects [38], which could lead to 
the cleavage of FVa and FVIIIa in reducing thrombin generation. However, these 
observations do not take into account more recent findings demonstrating the role of H4 in 
promoting prothrombin autoactivation.  Since this process takes up to 8 hours to occur and 
thrombin generation occurs within minutes, this prompted me to investigate the role of co-
factors in histone-induced prothrombin activation. FVa interacts with both fragment 1 and 2 
of prothrombin and facilitates prothrombin cleavage and thrombin generation by FXa.  H4 
binds to fragments 1 and 2 of prothrombin and, in a manner that appears similar to that of 
FVa, facilitates FXa-induced prothrombin cleavage and thrombin generation. 
Histones H4 and H3 showed higher binding responses to prothrombin than the other histones, 
with H4 having the greatest affinity.  This was also shown to have functional significance 
whereby only H4 and H3 were able to facilitate the cleavage of prothrombin in the presence 
of Factor Xa.  However, there was a marked difference in the ability of histone H4 and H3 to 
generate thrombin.  This could be due to the ability of different histones facilitating the 
cleavage of different sites in the presence of FXa.  In fact, only H4 was able to produce a 34 
kDa band when incubated with prothrombin in the presence of Factor Xa.  Since prothrombin 
has 3 cleavage sites (Arg-155, Arg-271 and Arg-320), that upon cleavage lead to the 
generation of active thrombin; this would suggest that only H4 is able to facilitate the 
sufficient cleavage of each of these three sites.  H1, H2A and H2B could not facilitate the 
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cleavage of prothrombin by FXa.  H3 and H4 with FXa generate bands for the correct 
molecular weight of prethrombin-1 and prethrombin-2, which would be consistent with 
cleavage at Arg-155 and Arg-271 respectively.  Only H4 was able to generate a 34 kDa B-
chain, band which would be formed through cleavage of Arg-320 of prothrombin, resulting in 
the generation of active thrombin. 
Coagulation activation is a major feature of histone-induced toxicity observed in vitro and in 
vivo. Our group have demonstrated a link between extracellular histones and a marker of 
thrombin generation, plasma thrombin–anti-thrombin (TAT) complexes, in both histone-
infusion and trauma mouse models [48]. Moreover, TAT levels could be significantly 
reduced upon infusion of MahscFv. Furthermore, this was shown to have translational 
relevance to trauma patients, whereby plasma TAT levels were significantly increased and 
also correlated with circulating histone levels.  This chapter highlights a potential functional 
link between elevated histone levels and increased thrombin generation previously 
demonstrated in vivo and sheds light on the role of extracellular histones in the coagulation 
cascade. 
 
5.5 Conclusion  
In conclusion, both anti-histone antibodies and heparin are able to significantly reduce 
histone-induced prothrombin cleavage and thrombin generation. Although more striking 
results are obtained using heparin than anti-histone scFvs, the side effects of heparins, 
particularly on platelets, may become an obstacle for its clinical use. Therefore, further 




Chapter 6 General Discussion 
 
6.1 Discussion 
The toxicity of extracellular histones is now well documented and it is likely to play an 
important role in disease progression whenever there is extensive cell death and this can lead 
to multiple organ failure [14, 48]. However, the reagents suitable as anti-histone therapy are 
very limited. It is known that APC [14] and heparin [92] are able to detoxify histones. 
However, they are anticoagulant and likely to cause bleeding and therefore cannot be used in 
critical illness especially when there is thrombocytopenia. Non-anticoagulant APC or heparin 
is under development but they may have other side effects, for example heparin-induced 
thrombocytopenia [202]. In contrast, anti-histone antibodies are specific and may have fewer 
side effects and therefore hold particular promise as suitable anti-histone reagents for clinical 
use.  
For therapeutic purposes, large quantities of anti-histone antibodies are required. The whole 
intact antibody is difficult to produce to match these requirements. The scFv has greatly 
simplified the structure compared to the whole antibody [140]. This makes it practical to 
produce a functional antibody fragment using recombinant DNA technology [140]. However, 
most scFvs have solubility problems and have to be denatured and refolded. In this work, I 
have successfully overcome this problem by on-column refolding and produced sufficient, 
soluble and functional anti-histone scFvs for both in vitro and in vivo experiments.  
It is well documented that antibodies have species specificity.  As such, if a therapeutic 
antibody contains a sequence from a different species then this antibody could serve as an 
antigen, whereby the host response would be to produce an antibody against this therapeutic 
agent, i.e. a human anti-mouse antibody can be induced. For clinical use, humanised 
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antibodies are essential to avoid the immune response [203]. In this work, I first used the 
traditional methodology of replacing the CDRs of human IgG1 with CDRs from mouse anti-
histone antibodies, to generate a humanised anti-histone scFv and its anti-histone properties 
have been proven. However, the mouse CDRs may also have the risk, albeit much lower, risk 
of inducing an immune response to produce anti-mouse CDR antibodies. To overcome this 
disadvantage, I chose another approach to generate human anti-histone antibodies. 
As it is known that anti-histone antibodies exist in the sera from patients with SLE or other 
autoimmune diseases [204], these human anti-histone antibodies are theoretically less likely 
to cause an immune response when used in patients. There are many methodologies to 
generate human antibodies based on B cell libraries, such as phage display, RNA-display and 
DNA-display [149]. However, these techniques are fairly labour intensive and time 
consuming. In this work, I explored a new approach, which is to pull down anti-histone 
antibodies directly from patients’ sera and then to determining its peptide sequences using 
MS/MS, and finally reproduced the antibody on a large scale using recombinant DNA 
technology. In this thesis, I have demonstrated that this approach is a simple, fast and 
practical way of reproducing human antibodies. The new human anti-histone antibody I 
produced has great potential to be developed as a clinically useful anti-histone reagent.  
Work from our group has already highlighted the potential benefits of the blocking histone 
cytotoxicity to reduce ALI in trauma [48] and cardiac dysfunction in sepsis [37]. Central to 
their pathologies is the role of excessive thrombin generation and our finding on H4 induced 
prothrombin activation into thrombin lends support to the concept of blocking histones, 
especially when thrombin generation becomes maladaptive and spills into DIC. The 
challenge is to design and undertake much needed clinical studies in the timing of 
antithrombin intervention as well as the duration of such treatments. Future work will be 
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along these lines to realise the promise of saving lives and reducing the poor outcome in 
critical illness.  
In this work, I have also applied the pull down technique to the identification of histone-
binding proteins in human sera, both normal and during critical illness. Using highly stringent 
conditions, I have identified some interesting proteins, such as prothrombin and anti-
thrombin. Since it is well documented that extracellular histones are potent pro-coagulation 
reagents, this finding may explain why histones can trigger blood clotting cascades. Through 
a thorough study, I find that histones, particularly H4, bind to fragment 1 and 2 of 
prothrombin, which facilitates the cleavage of prothrombin by Factor Xa to generate active 
thrombin, the latter activates coagulation. This is the first study that elucidates the molecular 
mechanism behind histone-enhanced thrombin generation.  
 
6.2 Conclusion  
In summary, my work not only creates new methodologies in producing human anti-histone 
antibodies, which have been used in many in vitro and in vivo experiments, but also gains 
new scientific findings in understanding how extracellular histones promote thrombin 
generation. However, due to the limitation of time and resources, much work is needed to 
further characterize both the biological and clinical impact of these findings. 
 
6.3 Further work 
1. The functional roles of human anti-histone scFv was only tested in vitro. In the near future, 
we will use the antibody fragment in different animal models, such sepsis and pancreatitis to 
evaluate its protective roles in diseases with high levels of circulating histones. 
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2. The roles of the interaction between histones and anti-thrombin will be explored. In 
conjunction with the roles of histones in affecting prothrombin and fibrinogen, I will try to 
dissect the fundamental roles and mechanisms of histones in thrombosis, DIC and organ 
failure. 
3. I will further optimise the new approach to producing human antibodies to establish a 
standard system in order to apply this approach to other diseases, particularly for epidemics 
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Appendix 1 Reagents 
 
                              Reagent                              Company 
10 × PBS  Fisher Scientific (Hampton, USA) 
10 × TBE Geneflow Ltd (Staffordshire, UK) 
10 × Tris/Glycine Geneflow Ltd (Staffordshire, UK) 
10 × Tris/Glycine/SDS Geneflow Ltd (Staffordshire, UK) 
2-Log DNA Ladder (0.1-10.0 kb)  New England Biolabs (Massachusetts, USA) 
2-macaptoethanol Sigma-Aldrich (St. Louis, Missouri, USA) 
2-Propanol (Isopropanol)  Sigma-Aldrich (St. Louis, Missouri, USA) 
Acetic Acid Thermo Fisher Scientific (Waltham, USA) 
Acetone  Thermo Fisher Scientific (Waltham, USA) 
Acrylamide Geneflow Ltd (Staffordshire, UK) 
Activated Protein C (APC) Haematologic Technologies Inc. (Cambridge, 
UK) 
Ammonium Persulfate Sigma-Aldrich (St. Louis, Missouri, USA) 
Ampicillin sodium salt Sigma-Aldrich (St. Louis, Missouri, USA) 
Anti-Histone H3 antibody abcam (Cambridge, UK) 
Asp-N Promega (Madison, WI USA) 
BamHI New England Biolabs (Massachusetts, USA) 
Bovine Serum Albumin (BSA)  Sigma-Aldrich (St. Louis, Missouri, USA) 
Brilliant Blue R  Sigma-Aldrich (St. Louis, Missouri, USA) 
Bromophenol Blue Sigma-Aldrich (St. Louis, Missouri, USA) 
CaCl2 BDH, VWR (Leicestershire, UK) 
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Calf Thymus Histone Roche (West Sussex, UK) 
Chymotrypsin  Promega (Madison, WI USA) 
CNBr-activated Sepharose 4B media  GE Healthcare (Buckinghamshire, UK) 
Creatine Monohydrate Sigma-Aldrich (St. Louis, Missouri, USA) 
DC™ Protein Assay Bio-Rad (Hercules, USA) 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich (St. Louis, Missouri, USA) 
EDTA Sigma-Aldrich (St. Louis, Missouri, USA) 
EGTA Sigma-Aldrich (St. Louis, Missouri, USA) 
Ethanol Thermo Fischer Scientific (Loughborough, 
UK) 
Ethanolamine Sigma-Aldrich (St. Louis, Missouri, USA) 
Extravidin-Peroxidase Staining Kit Sigma-Aldrich (St. Louis, Missouri, USA) 
EZ-Link™ Plus Activated Peroxidase Thermo Fisher Scientific (Waltham, USA) 
Fetal bovine serum  Sigma-Aldrich (St. Louis, Missouri, USA) 
Fibronectin Sigma-Aldrich (St. Louis, Missouri, USA) 
Gelatin  Sigma-Aldrich (St. Louis, Missouri, USA) 
Gelatine from Bovine Skin Sigma-Aldrich (St. Louis, Missouri, USA) 
Gibco™ L-Glutamine 200 mM Invitrogen (Thermo Fisher Scientific, 
Waltham, USA) 
Gibco™ Penicillin-Streptomycin liquid from 
Invitrogen 
Invitrogen (Thermo Fisher Scientific, 
Waltham, USA) 
Glu-C Promega (Madison, WI USA) 
Glucose Sigma-Aldrich (St. Louis, Missouri, USA) 
Glycerol Sigma-Aldrich (St. Louis, Missouri, USA) 
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Glycine Sigma-Aldrich (St. Louis, Missouri, USA) 
HCl (Hydrochloric acid) BDH, VWR (Leicestershire, UK) 
HEPES Sigma-Aldrich (St. Louis, Missouri, USA) 
HEPES Sigma-Aldrich (St. Louis, Missouri, USA) 
HiSpeed Plasmid Midi Kit (25) QIAGEN (Venlo, Netherlands) 
Histone H1
0
 Human, Recombinant  New England Biolabs (Massachusetts, USA) 
Histone H2A Human, Recombinant New England Biolabs (Massachusetts, USA) 
Histone H2B Human, Recombinant New England Biolabs (Massachusetts, USA) 
Histone H3.1 Human, Recombinant New England Biolabs (Massachusetts, USA) 
Histone H4 Human, Recombinant  New England Biolabs (Massachusetts, USA) 
Hydrogen peroxide (H2O2) Sigma-Aldrich (St. Louis, Missouri, USA) 
IGEPAL® CA-630 Sigma-Aldrich (St. Louis, Missouri, USA) 
Imidazole Sigma-Aldrich (St. Louis, Missouri, USA) 
Immobilon Western Chemiluminescent HRP 
Substrate 
Millipore (Watford, UK) 
Immobilon®-P PVDF Membrane (0.45 µm) Millipore (Billerica, USA) 
Immobilon™ Western Chemiluminescent 
HRP Substrate 
Millipore (Billerica, USA) 
Instant Dried Skimmed Milk Tesco (Liverpool, UK) 
IPTG (Isopropyl-β-D-thiogalactopyranoside) MELFORD (Suffolk, UK) 
KCl BDH, VWR (Leicestershire, UK) 
L-Ascorbic Acid Sigma-Aldrich (St. Louis, Missouri, USA) 
L-Glutamine Sigma-Aldrich (St. Louis, Missouri, USA) 
L-Glutathione oxidized  Sigma-Aldrich (St. Louis, Missouri, USA) 
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L-Glutathione reduced Sigma-Aldrich (St. Louis, Missouri, USA) 
Lys-C Promega (Madison, WI USA) 
Methanol Thermo Fisher Scientific (Waltham, USA) 
MgCl2 BDH, VWR (Leicestershire, UK) 
N,N,N′,N′-Tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich (St. Louis, Missouri, USA) 
N-Acetylheparin sodium salt Sigma-Aldrich (St. Louis, Missouri, USA) 
NaCl Sigma-Aldrich (St. Louis, Missouri, USA) 
NaH2PO4 BDH, VWR (Leicestershire, UK) 
NdeI New England Biolabs (Massachusetts, USA) 
Ni-NTA QIAGEN (Venlo, Netherlands) 
Penicillin/Streptomycin  Sigma-Aldrich (St. Louis, Missouri, USA) 
pET-16b  Novagen (Darmastadt, Germany) 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich (St. Louis, Missouri, USA) 
Phosphate Buffered Saline (PBS), 10 × 
Solution  
Thermo Fisher Scientific (Waltham, USA) 
Pierce® Chromatography Cartridges Protein 
A/G 
Thermo Fisher Scientific (Waltham, USA) 
Propidium iodide solution  Sigma-Aldrich (St. Louis, Missouri, USA) 
Prostaglandin E1 Sigma-Aldrich (St. Louis, Missouri, USA) 
Protease inhibitor cocktail  Calbiochem, Merck (Nottingham, UK) 
Protease type XIV  Sigma-Aldrich (St. Louis, Missouri, USA) 
QIAprep Spin Miniprep Kit (250) QIAGEN (Venlo, Netherlands) 
QIAquick Gel Extraction Kit QIAGEN (Venlo, Netherlands) 
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Quick Start™ Bovine Serum Albumin (BSA) 
standard set 
Bio-Rad (Hercules, USA) 
Rubidium Chloride Sigma-Aldrich (St. Louis, Missouri, USA) 
Sensor Chip SA GE Healthcare (Buckinghamshire, UK) 
Sodium bicarbonate  Sigma-Aldrich (St. Louis, Missouri, USA) 
Sodium carbonate  Sigma-Aldrich (St. Louis, Missouri, USA) 
Sodium cyanoborohydride solution Sigma-Aldrich (St. Louis, Missouri, USA) 
Sodium Dodecyl Sulphate (SDS) Sigma-Aldrich (St. Louis, Missouri, USA) 
Sodium orthovanadate  Sigma-Aldrich (St. Louis, Missouri, USA) 
T4 DNA Ligase  New England Biolabs (Massachusetts, USA) 
Taurine Sigma-Aldrich (St. Louis, Missouri, USA) 
Thrombin-α (IIα) Haematologic Technologies Inc. (Cambridge, 
UK) 
TMB Substrate Reagent Set  BD (Franklin Lakes, USA) 
Tris base Thermo Fisher Scientific (Waltham, USA) 
Triton X-100 BDH, VWR (Leicestershire, UK) 
Trypisn Promega (Madison, WI USA) 
Trypsin-EDTA Sigma-Aldrich (St. Louis, Missouri, USA) 
TWEEN® 20 Sigma-Aldrich (St. Louis, Missouri, USA) 
Versene Solution  Life techonologies (Waltham, USA) 
WST-8 cell proliferation assay kit Enzo life sciences (Exeter, UK) 





Appendix 2 Buffers 
 
                             Buffer                         Components 
1 × PBS 137 mM NaCl, 2.7 mM KCl, 11.9 mM 
Phosphate Buffer 
1 × TBS-Tween buffer saline For 1 litre: 100 ml of TBS 10X + 900 ml 
distilled water + 1ml Tween-20 
10 × TBS buffer for western blotting 1.5M NaCl, 0.2M Tris-HCl, ddH2O, pH 7.4 
4 × Laemmli buffer  62.5 mM Tris-HCl, pH6.8, 10% (v/v) 
Glycerol, 5% (v/v) β-mecaptoethanol, 3% 
(w/v) SDS, 0.008% (w/v) bromophenol blue 
Biosensor suspension buffer 1 100 NaCl, 20 Tris-HCl, pH 7.4 
Biosensor suspension buffer 2 100 NaCl, 20 Tris-HCl, pH 7.4, 2 mM EGTA 
Biosensor suspension buffer 3 100 NaCl, 20 Tris-HCl, pH 7.4, 2mM CaCl2 
Brilliant Blue Staining Buffer For 1 Litre: 2.5 g Brilliant Blue R, 448 ml 
Methanol, 100 ml Acetic Acid, 452 ml H2O 
 
Clear lysis buffer (CLB) for cellular lysis 1% SDS, 10% Glycerol, 120mM Tris-HCL, 
25mM EDTA, H2O, protease inhibitor 
cocktail 1:500 dilution, sodium 
Orthovanadate 2nM, pH 6.8 
Coomasie blue de-staining buffer 10% Acetic acid, 30% Methanol, 60% H2O. 
CRP elution buffer  100 mM Tris-HCl, 100 mM NaCl, 2 mM 
EDTA, pH 8.0 
ELISA coating buffer  50 mM Na2CO3, 50 mM NaHCO3, pH9.6 
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Gel overlay buffer  100 mM NaCl, 50 mM Tris-HCl, 2 mM 
CaCl2, 2 mM DTT, 0.5 % (w/v) BSA, 0.25% 
(w/v) gelatin, 0.5% (v/v) IGEPAL
®
 CA-630 
Gel overlay washing buffer  100 mM NaCl, 50 mM Tris-HCl, 2 mM 
DTT, 0.5% (v/v) IGEPAL
®
 CA-630 
Harsh western blotting stripping buffer For 20 ml: 13.5 ml ddH2O, 4ml (10%) SDS, 
2.5 ml Tris-HCl pH 6.8 (0.5M) 
HEP buffer 140 mM NaCl, 2.7 mM KCl, 3.8 mM 
HEPES, 5 mM EGTA, pH7.4 
HEPES-Taurine buffer for rat 
cardiomyocytes isolation 
130mM NaCl, 5.4mM KCl, 1.4mM 
MgCl2.6H2O, 0.4mM NaH2PO4, 10mM 
creatine monohydrate, 20mM taurine, 10mM 
Glucose, 10mM HEPES and 0.75mM CaCl2, 
pH 7.3 
Histone binding protein elution buffer  100 mM Glycine, pH 3.0 
Histone binding protein washing buffer  PBS, 0.5% (v/v) Tween 20 
HL-1 cardiomyocytes freezing medium 95% FBS, 5% DMSO 
HL-1 cardiomyocytes growth medium 10 % FBS, 87% Claycomb medium, 
Penicillin/Streptomycin 100U/ml:100 μg/ml, 
0.1 mM Norepinephrine (in 30mM ascorbic 
acid), 2mM L-Glutamine 
Homogenization buffer for sub-cellular 
fractionation 
1% SDS, 10% Glycerol, 120mM Tris-HCL, 
25mM EDTA, H20, protease inhibitor 
cocktail 1:500 dilution, sodium 
orthovanadate 2nM, pH 6.8 
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HPT digestion buffer 20 mM HEPES, 150 mM NaCl, 5 mM 
CaCl2, 0.1% (v/v) PEG-8000, pH7.4  
MahscFv denaturation buffer  8 M urea, 50 mM Tris-HCl, pH7.4, 500 mM 
NaCl 
MahscFv denaturation elution buffer  8 M urea, 50 mM Tris-HCl, pH7.4, 500 mM 
NaCl, 250 mM Imidazole 
MahscFv denaturation washing buffer  8 M urea, 50 mM Tris-HCl, pH7.4, 500 mM 
NaCl, 50 mM Imidazole 
MahscFv lysis buffer 50 mM Tris-HCl, pH7.4, 500 mM NaCl 
MahscFv native purification elution buffer  50 mM Tris-HCl, pH7.4, 500 mM NaCl, 250 
mM Imidazole 
MahscFv native purification washing buffer  50 mM Tris-HCl, pH7.4, 500 mM NaCl, 50 
mM Imidazole 
MahscFv refolding dialysis buffer 1 8 M urea  
MahscFv refolding dialysis buffer 2 4 M urea 
MahscFv refolding dialysis buffer 3 2 M urea 
MahscFv refolding dialysis buffer 4 1 M urea 
MahscFv refolding dialysis buffer 5 0.5 M urea 
MahscFv refolding dialysis buffer 6 50 mM Tris-HCl, pH7.4, 500 mM NaCl 
MahscFv refolding dialysis buffer 7 PBS 
On-column refolding buffer 1 (wash buffer) 20 mM Tris-HCl, pH 8.0, 4 M Urea, 50 mM 
Imidazole 




On-column refolding buffer 3 20 mM Tris-HCl, pH7.4, 500 mM NaCl 
On-column refolding buffer 4 20 mM Tris-HCl, pH7.4, 100 mM NaCl, 5 
mM β-cyclodetrin 
On-column refolding buffer 5 20 mM Tris-HCl, pH7.4, 100 mM NaCl 
On-column refolding buffer 6 (Elution 
buffer) 
20 mM Tris-HCl, pH7.4, 100 mM NaCl, 300 
mM Imidazole 
On-column refolding denaturation buffer  40 mM Tris-HCl, pH 8.0, 8 M Urea 
PBS-T 1 × PBS, 0.1% Tween-20 
Permeabilization buffer for cardiomyocytes 
“skinning” 
Triton X-100 (1%) in PBS 
Platelet wash buffer  10 mM sodium citrate, 150 mM NaCl, 1 mM 
EDTA, 1% (w/v) dextrose, pH7.4 
Primary and secondary antibody buffer for 
Western blotting 
5% milk (in 1X TBS-Tween) or 2% BSA (in 
1X TBS-Tween) 
Refolding dialysis buffer 1 50 mM Tris-HCl, pH8.0, 1 M urea 
Refolding dialysis buffer 2 50 mM Tris-HCl, pH8.0, 1 M urea, 150 mM 
NaCl 
Refolding dialysis buffer 3 50 mM Tris-HCl, pH8.0, 1 M urea, 3 mM 
GSH, 1 mM GSSG 
Refolding dialysis buffer 4 50 mM Tris-HCl, pH8.0, 1 M urea, 150 mM 
NaCl, 3 mM GSH, 1 mM GSSG 
Resolving SDS-PAGE gel buffer 1.5 M Tris-HCl, 0.4% SDS, pH 8.8 
RF1  100 mM RbCl, 50 mM MnCl2, 30 mM KAc, 
10 mM CaCl2, 15% (v/v) Glycerol, pH5.8 
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RF2 10 mM MOPS, 10 mM RbCl,75 mM CaCl2, 
15% (v/v) Glycerol, pH6.8 
SDS-PAGE electrophoresis buffer 0.025M Tris, 0.192M Glycine, 0.1% SDS 
SDS-PAGE transfer buffer 0.025M Tris, 0.192M Glycine 
Sensor Chip SA Regeneration buffer  20 mM HCl 
Stacking SDS-PAGE gel buffer 
 
0.5 M Tris-HCl, 0.4% SDS, pH 6.8 
Tyrode buffer for rat cardiomyocytes 
preservation and experimentation 
140mM NaCl, 5.4mM KCl, 10mM Glucose, 
10mM HEPES, 1mM CaCl2, 1mM MgCl2, 
pH 7.35 
Tyrode’s buffer 134 mM NaCl, 12 mM NaHCO3, 2.9 mM 
KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 10 
mM HEPES, pH7.4  
Western blot block reagent  5% 5% Instant dried skimmed milk (Tesco, 











Appendix 3 Equipment and software  
 
                       Equipment/Software                              Use 
1. 1.4F pressure-volume catheter (SPR-839) 
and a pressure volume system (Millar 
Instruments) and software Miller PVAN 2.9 
software (Millar Instruments). 
In vivo haemodynamic assessment of mice 
ventricular function 
2. ACUSON Sequoia C256 Echocardiography 
System 
Transthoracic echocardiography assessment 
on mice 
Analog-Digital converter interface (Digidata 
120B; Molecular Devices, US) 
Ca
2+ 
fluorescence signals processing and 
digitisation 
BD FACSCalibur  Cell death sorting 
Beckman Coulter Optima-Max 
ultracentrifuge and rotor TLA 120.2 
Ultracentrifugation of sub-cellular fractions 
Biacore™ X100 Insight of protein and protein interaction in 
order to calculate the kinetics, affinity and 
specificity 
BioMAT Class II Microbiological Safety 
Cabinets 
Tissue culture 
Cell homogenizer (Ultra-Turrax T8, IKA 
Labortechnik, Staufen, Germany) 
Homogenization of mice heart  
Confocal microscope (Carl Zeiss, LSM 710) 
and Software (Zen 2011) 
Ca
2+ 
flux measurement in HL-1 
cardiomyocytes 




G box (Syngene) and software GeneSnap 
(Syngene) 
Gel imaging for fluorescence and 
chemiluminescence 
Gallenkamp Magnetic Stirrer Stirring various buffers 
IonOptix, MyoCam-S video edge-recognition 
system(Dublin, Ireland) and software 
IonWizard 6.0 
Recording of rat and HL-1 cardiomyocyte 
contractility 
Langendorff Apparatus  Rat cardiomyocytes isolation 
Microplate reader (Multiskan Spectrum, 
Thermo electron corporation) and software 
SkanIt RE for MSS 2.2 
Microplate reader 
Microprocessor pH meter (HI 221) – Hannah 
instrument 
pH measurement of various buffers 
3. Microsoft excel (2010) Data arrangement and organization 
4. Microsoft power point (2010) Figures preparation 
5. Microsoft word (2010) Thesis preparation 
Mini-PROTEAN® Tetra Cell - Bio-Rad Western blotting electrophoresis system 
MODULAR ANALYTICS EVO analyser 
(Roche) 
Measurement of cTnT levels in human serum 
and plasma 
Nanodrop ND-1000 Spectrophotometer Measure DNA and protein concentration  
NanoDrop ND-1000 Spectrophotometer Operation of Nanodrop ND-1000 
Oertling NA164 Sensitive balance 
Optoscan monochromator fluorescence Measurement of [Ca
2+
]i in rat cardiomyocytes 
156 
 
photometry system (Cairn Research, 
Faversham, Kent, UK). 
PL3504 PowerLab 4/35 (ADInstruments) ECG recording on mice 
Platelet aggregation profiler PAP-8E Exam platelet aggregation with histones 
treatment, and test the protection with Abs 
against histones 
Platform shaker STR6 (Stuart scientific) Platform shaker 
Sartorius TE214S digital gram scale Digital balance 
SciQuip Ltd centrifuge (1-15K) Centrifugation of various samples 
SciQuip Ltd centrifuge (3-16 PK) Centrifugation of various samples 
SnapGene
®
 Visualise and document DNA cloning, 
especially study plasmid.  
6. SPSS (PASW) 18 Statistical analysis (Including ANOVA test)  
 
Ultrasonic cell disruptor (Misonix Inc., US) Cell disruption and protein lysates 
preparation 
VXR basic Vibrax® - Ika General shaker 
Water bath (Grant GR150) Temperature preservation/preparation of 
various buffer 
 
